

CORRECTED
VERSION *

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : A61K 39/00, 39/108, C07K 13/00 C07K 15/04, C12N 15/00	A1	(11) International Publication Number: WO 85/05037 (43) International Publication Date: 21 November 1985 (21.11.85)
(21) International Application Number: PCT/DK85/00045 (22) International Filing Date: 2 May 1985 (02.05.85) (31) Priority Application Number: 2190/84 (32) Priority Date: 2 May 1984 (02.05.84) (33) Priority Country: DK (71) Applicant (for all designated States except US): SYN-TEK AB [SE/SE]; Sofiehemsvägen 4A, S-902 39 Umeå (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): LINDBERG, Fred-erik, Carl, Peter [SE/SE]; Hedgrindsgatan 3, S-811 61 Sandviken (SE). LUND, Björn, Olof [SE/SE]; Stipendiegränd 14F, S-902 40 Umeå (SE). BAGA, Britt, Monika [SE/SE]; Biologigränd 36, S-902 40 Umeå (SE). NORGREN, Mari, Elisabet [SE/SE]; Härads- shövdingegatan 30B, S-902 45 Umeå (SE). GÖRANS- SON, Mikael [SE/SE]; Språkgränd 41, S-902 40 Umeå (SE). UHLIN, Berndt, Eric, Anund [SE/SE];		Rödhakevägen 20, S-902 37 Umeå (SE). NOR- MARK, Jan, Staffan [SE/SE]; Zakrisvägen 28, S-913 00 Holmsund (SE). LARK, David, Lee [US/SE]; Trastvägen 9A, S-902 37 Umeå (SE). (74) Agent: PLOUGMANN & VINGTOFT; 11 Sankt Annæ Plads, DK-1250 Copenhagen K (DK). (81) Designated States: AT (European patent), AU, BE (Eu- ropean patent), CH (European patent), DE (Euro- pean patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU, US. Published <i>With international search report.</i>
(54) Title: ADHESIN ANTIGENS, ANTIBODIES AND DNA FRAGMENT ENCODING THE ANTIGEN, METH- ODS AND MEANS FOR DIAGNOSIS AND IMMUNIZATION ETC. (57) Abstract An antigen which, as its major immunizing component, comprises a determinant of an adhesin polypeptide or an immunogenically active subsequence thereof or a precursor therefor which is convertible to an immunogenically active form, antibodies against which determinant react with the adhesin polypeptide produced by pathogenic adhesin-forming bacteria which adhere to mammalian tissue, antibodies against such antigen, and DNA expressing, as a principal gene pro- duct thereof, such antigen.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 39/00, 39/108, C07K 13/00 C07K 15/04, C12N 15/00		A1	(11) International Publication Number: WO 85/ 05037 (43) International Publication Date: 21 November 1985 (21.11.85)
(21) International Application Number: PCT/DK85/00045 (22) International Filing Date: 2 May 1985 (02.05.85) (31) Priority Application Number: 2190/84 (32) Priority Date: 2 May 1984 (02.05.84) (33) Priority Country: DK (71) Applicant (for all designated States except US): SYN- TEK [DK/DK]; Sofiehemsvägen 4A, DK-902 39 Umeå (DK). (72) Inventors; and (75) Inventors/Applicants (for US only) : LINDBERG, Fred- erik, Carl, Peter [SE/SE]; Hedgrindsgatan 3, S-811 61 Sandviken (SE). LUND, Björn, Olof [SE/SE]; Stipen- diegränd 14F, S-902 40 Umeå (SE). BÅGA, Britt, Monika [SE/SE]; Biologigränd 36, S-902 40 Umeå (SE). NORGREN, Mari, Elisabet [SE/SE]; Härads- shövdingegatan 30B, S-902 45 Umeå (SE). GÖRANS- SON, Mikael [SE/SE]; Språkgränd 41, S-902 40 Umeå (SE). UHLIN, Bernt, Eric, Anund [SE/SE];		Rödhavevägen 20, S-902 37 Umeå (SE). NOR- MARK, Jan, Staffan [SE/SE]; Zakrisvägen 28, S-913 00 Holmsund (SE). LARK, David, Lee [US/SE]; Trastvägen 9A, S-902 37 Umeå (SE). (74) Agent: PLOUGMANN & VINGTOFT; 11 Sankt Annæ Plads, DK-1250 Copenhagen K (DK). (81) Designated States: AT (European patent), AU, BE (Eu- ropean patent), CH (European patent), DE (Euro- pean patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU, US. Published With international search report.	
(54) Title: ADHESIN ANTIGENS, ANTIBODIES AND DNA FRAGMENT ENCODING THE ANTIGEN, METH- ODS AND MEANS FOR DIAGNOSIS AND IMMUNIZATION ETC.			
(57) Abstract An antigen which, as its major immunizing component, comprises a determinant of an adhesin polypeptide or an immunogenically active subsequence thereof or a precursor thereof which is convertible to an immunogenically active form, antibodies against which determinant react with the adhesin polypeptide produced by pathogenic adhesin-forming bacteria which adhere to mammalian tissue, antibodies against such antigen, and DNA expressing, as a principal gene product thereof, such antigen.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LJ	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

"Adhesin antigens, antibodies and DNA fragment encoding the antigen, methods and means for diagnosis and immunization etc".

The present invention relates, *inter alia*, to an antigen useful, e.g., for the immunization of a mammal, an antibody raised against it, and a vaccine produced from it.

- 5 Antigens composed of several proteins which together form a distinct phenotype in a pathogenic bacterial strain or species, and which must therefore be assumed to contain a large number of immunogenic determinants, are well known. However, such antigens - and vaccines produced from them - have a number of disadvantages: in particular, they have a tendency to be too selective in that, on immunization, antibodies are formed against each of these immunogenic determinants which together identify the one particular bacterial strain from which the antigen has been derived, but not other bacterial strains of the same species so that immunization is only effected against this particular strain, but not other, closely related strains of the same species.

The present invention is an attempt to overcome these disadvantages by providing an antigen which substantially only comprises the immunogenic determinant(s) which lead to the desired immunity and which is furthermore not limited to one particular strain of the pathogenic bacteria in question.

It has become increasingly clear that the capacity of many pathogenic bacteria to adhere to the surface of cells is of primary importance for the initiation of many infectious diseases (Beachey, *J. Infect. Dis.* 143, 1981, pp. 325-345). This adhesion capacity is caused by the presence of receptors on mammalian tissue cells, such as epithelial cells, or on mammalian erythrocytes, which receptors, due to their configuration, form bonds with adhesin polypeptides. (In the present context, the term "adhesin polypeptide" is intended to indicate both a polypeptide specifically required for the adhesion phenotype and, more generally, a polypeptide in whose absence adhesion does not take place (for whatever reason).) Each receptor is assumed to bond with a different adhesin structure. The receptor may be a peptide receptor, such as an amino acid present on a sugar, or - more usu-

ally - a carbohydrate such as neuramic acid-(2+3)-galactose, manno-
se- α -(1+2)-mannose or digalactoside (the α -D-Galp-(1+4)- β -D-Galp
moiety present in the globoseries of glycolipids which in the present
context is occasionally termed the globoside).

- 5 In many pathogenic bacteria, the adhesin polypeptide proper is be-
lieved to form only part of a larger sequence of polypeptides which
are all, in one way or another, related to the adhesion function (e.g.
polypeptides which mediate the transport of the adhesin through the
cell wall or anchor it to the outer surface of the cell wall and so on),
10 and in accordance with the aim of the present invention, a specific
adhesin polypeptide is identified among the other polypeptides of the
sequence and used as an antigen. This is thought to constitute a less
selective identification marker so that antibodies will not only be
raised against the strain from which the antigen is derived but also
15 against the other pathogenic strains of the same bacterial species.

- Accordingly, the present invention relates to an antigen which, as its
major immunizing component, comprises a determinant of an adhesin
polypeptide or an immunogenically active subsequence thereof or a
precursor therefor which is convertible to an immunologically active
20 form, antibodies against which determinant react with the adhesin
polypeptide produced by pathogenic adhesin-forming bacteria which
adhere to mammalian tissue. This antigen may comprise an amino acid
sequence of at least 5 amino acids and up to the entire amino acid
sequence of the adhesin polypeptide.

- 25 The adhesin polypeptide may conveniently be derived from adhesin-
forming bacteria. This group of bacteria comprises both grampositive
and gramnegative bacteria, and the bacterial species of the greatest
interest in the present context from which it would be advantageous
to derive one or more specific adhesin polypeptides are uropathogenic
30 or enteropathogenic strains of *Escherichia coli* or other enteric bac-
teria or oral bacteria, *Neisseria gonorrhoeae*, *Neisseria meningitidis*,
Neisseria catarrhalis, *Yersinia* spp., *Pseudomonas aeruginosa* or other
Pseudomonas spp., *Moraxella bovis* or other *Moraxella* spp., *Bac-*
teroides nodosus, *Staphylococcus* spp., *Streptococcus* spp. or *Borde-*
35 *tella* spp. such as *Bordetella pertussis*.

Alternatively, the adhesin polypeptide may be prepared synthetically, as described below.

For some pathogenic bacteria in this group, there is evidence that filamentous structures termed pili (fimbriae) projecting from the cell wall are in some way connected with adhesion, and therefore - and because the pili are easily purified - whole pili preparations have been used as antigens in vaccines, e.g. gonococcus pili antigen (tested in US Army field tests).

Previous investigators working with pili preparations went to great lengths in attempts to prepare "pure" pili protein for protein characterization and immunization, and their efforts were apparently successful in that their preparations only showed one band in SDS gels, (US Patent No. 4,443,431 (Buchanan T.M. et al); Saliot I.E. & E.C., Gottlisch, J., *Exp. Med.* 146, 1977, p. 1169; Klemm P., I. Orskov & F. Orskov, *Infect. and Immunity* 36, 1982, p. 462; Schoolnik G.K. et al, *J. Exp. Med.* 159, 1984, p. 1351; Svanborg E.C., *Prog. Allergy* 33, 1983, p. 189). The obtained pili protein preparations exhibited at least three functions. The first function was the ability to form polymers, presumably through hydrophobic binding processes; a property essential for the formation of a pilus filament from monomeric subunits. The second property was the ability to engender antibodies; a property which would be essential for any attempts to use the protein as a vaccine. The third property was the ability to adhere to cell surface receptors. Since the investigators were not able to identify more than one protein in their pili protein preparations as well as in the pili themselves, it was concluded that the pili were polymeric aggregates of identical monomeric protein subunits, each subunit having all three of the above-described functions, (US Patent No. 4,443,431 (Buchanan T.M. et al); Rothbard J.B., *PNAS* 82, 1985, p. 915). However, as mentioned previously, the intact whole pili from a single species has great antigenic diversity. In addition, it has been demonstrated that when used as a vaccine, intact whole pili of a single antigenic type produce antibody primarily to that single antigenic type rather than shared pili antigens. Previous investigators have chemically cleaved the purified pilus subunit into fragments with

the proposed functions: Polymerization function, common antigen function, and binding function. Each individual function was identified with a separate fragment of the purified pilus subunit. Thus, it has been assumed that purified pili protein preparations contain a single
5 protein - the pilin monomer. This pilin monomer has been chemically cleaved and assumed to contain the binding function and the principal antigenicity - the same as the polymerized pure pilus protein.

Extensive studies carried out by the applicants demonstrate, however, that the supposed pure pili protein in fact consists of several protein
10 fractions with separate functions. In fact, the pilus filament is not responsible for the cell surface binding but a minor component considered to be a contaminant which is most likely associated with the filament is what is responsible for the cell surface binding. This unique observation could only be ascribed to the fact that the structural
15 formation of pili and the property of adhesion to digalactoside receptors can be genetically dissociated. Other mutated organisms retaining recognizable pili structures but being unable to adhere further confirmed the observation. The implication of the observation was further that the pilus protein, previously supposed to be pure,
20 must contain at least two fractions, one of which is a structural element involved in the actual formation of pili and the other one being a fraction responsible for the adhesion property. The fact that both fractions have antigenic properties opened up the possibility of engendering antibodies against only the adhesion-responsible fraction.

25 In the case of pilus-carrying bacteria, too, it is advantageous to produce an antigen showing less strain selectivity, if any, and such an antigen is provided by identifying and producing one or more components which form part of the structure of the entire pilus and which mediate the adhesion capacity specifically. In the present
30 context, such a component is termed a pilus adhesin polypeptide. In accordance with what is stated above, the pilus adhesin polypeptide usually comprises a minor component of the entire pilus amino acid sequence of pili derived from pathogenic pilus-forming bacteria and is distinct from the pilin (the subunit of the purified pilus, forming the
35 major part of the pilus fibre). Examples of pilus-forming bacteria

which are useful for this purpose are uropathogenic or enteropathogenic strains of *Escherichia coli*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Neisseria catarrhalis*, *Moraxella bovis* or other *Moraxella* spp. and *Bordetella pertussis*.

- 5 For the purposes of the present invention, the investigations disclosed herein have primarily been concerned with a uropathogenic strain of *E. coli* which gives rise to pyelonephritis. It should, however, be understood that the different *E. coli* genetic systems coding for pilus adhesins are very similar, and that consequently, it is
- 10 highly probable that such minor pilus components mediating adhesion exist for all types of pilus, i.e. also for pili from other bacteria than *E. coli*. The receptor responsible for the binding of the pathogenic pilus-forming bacteria due to the interlocking structures of the receptor - or part of the receptor - and adhesin molecules, respectively,
- 15 has been identified for uropathogenic *E. coli* to be the digalactoside, the α -D-Galp-(1 \rightarrow 4)- β -D-Galp moiety present in the globoseries of glycolipids, to which the bacteria may attach in the uroepithelium and which is also present on human erythrocytes as a part of the P bloodgroup antigens.
- 20 In the course of the research leading to the present invention, the inventors have identified the region on the chromosome of a uropathogenic *E. coli* strain which encodes Pap pili (pili associated with pyelonephritis) which is a 8.5 kb long region which has been found to code for at least eight different polypeptides. The present inventors
- 25 have also established the polypeptides the absence of which gives rise to non-adhesion of the *E. coli* cells. These polypeptides are therefore assumed to be responsible for the adhesion phenotype of uropathogenic *E. coli*. Consequently, the present invention also concerns an antigen of the amino acid sequence:
- 30 Met-Lys-Lys-Ile-Arg-Gly-Leu-Cys-Leu-Pro-Val-Met-Leu-Gly-Ala-Val-Leu-Met-Ser-Gln-His-Val-His-Ala-Val-Asp-Asn-Leu-Thr-Phe-Arg-Gly-Lys-Leu-Ile-Ile-Pro-Ala-Cys-Thr-Val-Ser-Asn-Thr-Thr-Val-Asp-Trp-Gln-Asp-Val-Glu-Ile-Gln-Thr-Leu-Ser-Gln-Asn-Gly-Asn-His-Glu-Lys-Glu-Phe-Thr-Val-Asn-Met-Arg-Cys-Pro-Tyr-Asn-Leu-Gly-Thr-Met-

Lys-Val-Thr-Ile-Thr-Ala-Thr-Asn-Thr-Tyr-Asn-Asn-Ala-Ile-Leu-Val-
Gln-Asn-Thr-Ser-Asn-Thr-Ser-Ser-Asp-Gly-Leu-Leu-Val-Tyr-Leu-
Tyr-Asn-Ser-Asn-Ala-Gly-Asn-Ile-Gly-Thr-Ala-Ile-Thr-Leu-Gly-Thr-
Pro-Phe-Thr-Pro-Gly-Lys-Ile-Thr-Gly-Asn-Asn-Ala-Asp-Lys-Thr-Ile-
5 Ser-Leu-His-Ala-Lys-Leu-Gly-Tyr-Lys-Gly-Asn-Met-Gln-Asn-Leu-Ile-
Ala-Gly-Pro-Phe-Ser-Ala-Thr-Ala-Thr-Leu-Val-Ala-Ser-Tyr-Ser or any
immunogenically active subsequence thereof, or

Met-Ile-Arg-Leu-Ser-Leu-Phe-Ile-Ser-Leu-Leu-Leu-Thr-Ser-Val-Ala-
Val-Leu-Ala-Asp-Val-Gln-Ile-Asn-Ile-Arg-Gly-Asn-Val-Tyr-Ile-Pro-
10 Pro-Cys-Thr-Ile-Asn-Asn-Gly-Gln-Asn-Ile-Val-Val-Asp-Phe-Gly-Asn-
Ile-Asn-Pro-Glu-His-Val-Asp-Asn-Ser-Arg-Gly-Glu-Val-Thr-Lys-Thr-
Ile-Ser-Ile-Ser-Cys-Pro-Tyr-Lys-Ser-Gly-Ser-Leu-Trp-Ile-Lys-Val-
Thr-Gly-Asn-Thr-Met-Gly-Gly-Gly-Gln-Asn-Asn-Val-Leu-Ala-Thr-
Asn-Ile-Thr-His-Phe-Gly-Ile-Ala-Leu-Tyr-Gln-Gly-Lys-Gly-Met-Ser-
15 Thr-Pro-Leu-Ile-Leu-Gly-Asn-Gly-Ser-Gly-Asn-Gly-Tyr-Gly-Val-Thr-
Ala-Gly-Leu-Asp-Thr-Ala-Arg-Ser-Thr-Phe-Thr-Phe-Thr-Ser-Val-
Pro-Phe-Arg-Asn-Gly-Ser-Gly-Ile-Leu-Asn-Gly-Gly-Asp-Phe-Gln-
Thr-Thr-Ala-Ser-Met-Ser-Met-Ile-Tyr-Asn or any immunogenically ac-
tive subsequence thereof, or

20 Met-Lys-Lys-Trp-Phe-Pro-Ala-Phe-Leu-Phe-Leu-Ser-Leu-Ser-Gly-
Gly-Asn-Asp-Ala-Leu-Ala-Gly-Trp-His-Asn-Val-Met-Phe-Tyr-Ala-
Phe-Asn-Asp-Tyr-Leu-Thr-Thr-Asn-Ala-Gly-Asn-Val-Lys-Val-Ile-
Asp-Gln-Pro-Gln-Leu-Tyr-Ile-Pro-Trp-Asn-Thr-Gly-Ser-Ala-Thr-Ala-
Thr-Tyr-Tyr-Ser-Cys-Ser-Gly-Pro-Glu-Phe-Ala-Ser-Gly-Val-Tyr-
25 Phe-Gln-Glu-Tyr-Leu-Ala-Trp-Met-Val-Val-Pro-Lys-His-Val-Tyr-Thr-
Asn-Glu-Gly-Phe-Asn-Ile-Phe-Leu-Asp-Val-Gln-Ser-Lys-Tyr-Gly-
Trp-Ser-Met-Glu-Asn-Glu-Asn-Asp-Lys-Asp-Phe-Tyr-Phe-Phe-Val-
Asn-Gly-Tyr-Glu-Trp-Asp-Thr-Trp-Thr-Asn-Asn-Gly-Ala-Arg-Ile-
Cys-Phe-Tyr-Pro-Gly-Asn-Met-Lys-Gln-Leu-Asn-Asn-Lys-Phe-Asn-
30 Asp-Leu-Val-Phe-Arg-Val-Leu-Leu-Pro-Val-Asp-Leu-Pro-Lys-Gly-
His-Tyr-Asn-Phe-Pro-Val-Arg-Tyr-Ile-Arg-Gly-Ile-Gln-His-His-Tyr-
Tyr-Asp-Leu-Trp-Gln-Asp-His-Tyr-Lys-Met-Pro-Tyr-Asp-Gln-Ile-
Lys-Gln-Leu-Pro-Ala-Thr-Asn-Thr-Leu-Met-Leu-Ser-Phe-Asp-Asn-
Val-Gly-Gly-Cys-Gln-Pro-Ser-Thr-Gln-Val-Leu-Asn-Ile-Asp-His-Gly-
35 Ser-Ile-Val-Ile-Asp-Arg-Ala-Asn-Gly-Asn-Ile-Ala-Ser-Gln-Thr-Leu-

Ser-Ile-Tyr-Cys-Asp-Val-Pro-Val-Ser-Val-Lys-Ile-Ser-Leu-Leu-Arg-
Asn-Thr-Pro-Pro-Ile-Tyr-Asn-Asn-Asn-Lys-Phe-Ser-Val-Gly-Leu-
Gly-Asn-Gly-Trp-Asp-Ser-Ile-Ile-Ser-Leu-Asp-Gly-Val-Glu-Gln-Ser-
Glu-Glu-Ile-Leu-Arg-Trp-Tyr-Thr-Ala-Gly-Ser-Lys-Thr-Val-Lys-Ile-
5 Glu-Ser-Arg-Leu-Tyr-Gly-Glu-Glu-Gly-Lys-Arg-Lys-Pro-Gly-Glu-
Leu-Ser-Gly-Ser-Met-Thr-Met-Val-Leu-Ser-Phe-Pro or any immunoge-
nically active subsequence thereof.

These amino acid sequences have been established by well-known methods as described in Example 5.

- 10 The absence of the latter two antigens have been positively demon-
strated to cause lack of binding to the globoside receptor in all cases
(cf. Example 3 below) and both of these are therefore assumed to be
an adhesin polypeptide proper, while the former antigen has been
shown to cause lack of binding in certain circumstances only (cf.
15 Example 3 below) and is therefore assumed to be required for anchor-
ing the adhesin polypeptide formed to the outer surface of the cell
wall.

It should be noted that the amino acid sequences shown above are the
precursor forms of the pilus adhesin polypeptides containing N-termi-
20 nal signal peptide-like sequences which are cleaved off when the
polypeptide is exported through the bacterial inner membrane.

In accordance with the principles of the invention, it is preferred
that the antigen of the invention be substantially free from other
components related to the adhesion function such as other components
25 of the pilus in order to avoid the formation of a wide variety of
antibodies when the antigen is used for immunization with the con-
sequent disadvantages outlined above. Most preferably, the antigen is
in substantially pure form, i.e. also free from other determinants
which are not in any way connected with adhesin formation but which
30 might give rise to undesirable immunological reactions.

In another aspect, the invention relates to an antibody raised a-
gainst, or directed substantially only against, an antigen as specified

above which, as its major immunizing component, comprises a determinant of an adhesin polypeptide or an immunogenically active subsequence thereof or a precursor therefor which is convertible to an immunologically active form. Such an antibody may be one which is
5 obtained by immunizing an immunizable animal with an antigen as defined above and obtaining antiserum such as immunoglobulins from the animal in a manner known *per se*. The immunization is preferably performed by means of a stabilized aqueous solution of the antigen; the stabilization agent may be a buffer such as phosphate buffered
10 saline or an adjuvant (also to further increase the antigenicity), and a suitable adjuvant is Freund's adjuvant or aluminium hydroxide. For immunization purposes, mice, rabbits, goats and sheep are the preferred animals, although pig immunoglobulins may also be employed as antibodies. The bleeding of the animal and the isolation of the antiserum
15 is performed according to well-known methods.

The antibody according to the invention is preferably also in substantially pure form which makes it useful for diagnostic purposes as described below.

Alternatively, the antibody may also be produced by a hybridoma
20 technique which is a well-known method for producing antibodies. In the hybridoma technique using for instance mice as the animals immunized, mice are immunized with the antigen in question and spleen cells from the immunized mice are fused with myeloma cells whereupon the fused hybridoma cells are cloned, antibody-producing cells are
25 grown in a suitable growth medium and the antibodies are recovered from the culture. The antibodies obtained by the hybridoma technique have the advantage of greater specificity and hence, greater accuracy of e.g. diagnosis. In a possible further step, using recombinant DNA techniques, the gene or genes encoding the antibody are transferred
30 from the hybridoma cell clone to a suitable vector, the hybrid vector is transformed to a suitable bacterial host, the host is grown in an appropriate medium and the resulting antibody is recovered from the culture. In this way, an improved yield of antibody may be obtained. The host may be one usually employed in the field of recombinant
35 DNA technology such as *Escherichia coli* or *Bacillus subtilis*.

A very important aspect of the present invention concerns a vaccine for immunizing a mammalian subject against diseases caused by pathogenic bacteria which adhere to mammalian tissue, which contains an immunogenically effective amount of an antigen as described above, optionally bound to a suitable carrier, together with an immunologically acceptable vehicle. This vehicle may be any vehicle usually employed in the preparation of vaccines, such as a diluent, suspending agent, adjuvant, etc.

In some cases, it will not be necessary to use a carrier as the antigen tends to polymerize with itself, but in instances where this is not the case, it may be advantageous to bind the antigen covalently to a carrier. This carrier will usually be a polymeric carrier and - especially when the vaccine is to be used to immunize human beings - it is important that it be physiologically acceptable. Synthetic non-toxic and/or non-allergenic carriers for the immobilization of antigens are known, e.g. from Arnon, *J. Immunological Methods* 61, 1983, pp. 261-273. Carriers of this type which are at present contemplated to be useful for this purpose are for instance poly-L-lysine and poly-D,L-alanine. A natural carrier may also be employed provided that it is non-toxic and non-allergenic.

The invention further relates to a method of preparing such a vaccine in which an immunogenically effective amount of an antigen as defined above, optionally bound to a suitable carrier, is combined, e.g. mixed, with an immunologically acceptable vehicle in an amount giving the desired concentration of the antigen in the vaccine preparation.

In a particular embodiment of the method of the invention, an immunogenically active amino acid sequence comprising at least 5 amino acids is covalently bound to the physiologically acceptable carrier, such as one of those mentioned above. The techniques for preparing fused polypeptides are known, e.g. from Casadaban et al., *Methods In Enzymology* 100, 1983, pp. 293-308.

In another embodiment of the method of the invention, the nucleotide sequence encoding an antigen as defined above is fused to the nucleo-

5 tide sequence encoding a physiologically acceptable carrier polypeptide, the fused DNA sequence is inserted into a suitable vector, the hybrid vector is transformed to a suitable bacterial host, the host is grown in an appropriate medium, and the fused polypeptide is recovered from the culture and optionally purified.

10 In a further aspect, the invention relates to a DNA fragment which comprises at least the nucleotide sequence encoding an antigen as defined above. It is preferred that the DNA fragment is one which encodes substantially no other antigen. This nucleotide sequence may be one which encodes the entire adhesin polypeptide or which encodes a precursor of an adhesin polypeptide which is convertible to an immunogenically active form or which encodes an immunogenically active subsequence of an adhesin polypeptide. In order to code for an amino acid sequence with immunogenic activity, the DNA fragment
15 should have a length of at least 5 codons (triplets). This DNA may be part of the genetic information residing on the chromosome of or on a plasmid from pathogenic adhesin-forming bacteria, representative examples of which are uropathogenic or enteropathogenic strains of *Escherichia coli* or other enteric bacteria or oral bacteria, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Neisseria catarrhalis*, *Yersinia* spp., *Pseudomonas aeruginosa* or other *Pseudomonas* spp., *Moraxella bovis* or other *Moraxella* spp., *Bacteroides nodosus*, *Staphylococcus* spp., *Streptococcus* spp. or *Bordetella* spp. such as *Bordetella pertussis*.
20 Thus, the DNA fragment may be the DNA or part of the DNA sequence coding for a pilus adhesin polypeptide which may be derived from a pathogenic pilus-forming bacterium, such as a uropathogenic or enteropathogenic strain of *Escherichia coli*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Neisseria catarrhalis*, *Moraxella bovis* or other
25 *Moraxella* spp., or *Bordetella pertussis*.
30

For the purpose of exemplification, the DNA fragment may be one which completely or partially comprises the DNA sequence coding for one or more of the adhesin polypeptides from a uropathogenic strain of *E. coli*. Consequently, the present invention relates to a DNA

fragment which - as its major element - is composed of the following DNA sequence:

ATGAAAAAGATAAGAGGTTTGTGTCTTCCGGTAATGCTGGGGGCAGTGT-
TAATGTCTCAGCATGTACATGCAGTTGATAATCTGACCTTCAGAGGAAA-
5 ACTGATTATTCCTGCCTGTACTGTAAGCAACACAACCTGTTGACTGGCAG-
GATGTAGAGATTTCAGACCCTGAGTCAAAATGGAAATCACGAAAAAGAGT-
TTACTGTGAATATGCGGTGTCCCTATAATCTGGGAACAATGAAGGTTAC-
GATAACGGCAACAAACACTTATAACAATGCTATTTTAGTTTCAGAATACA-
TCAAACACATCTTCTGATGGGTTACTCGTTTATCTTTATAACAGTAATG-
10 CAGGAAATATTGGGACTGCGATAACTTTAGGGACTCCATTTACGCCCGG-
AAAAATCACAGGTAATAATGCAGATAAACTATATCACTTCATGCCAAA-
CTTGATATQAAGGGAATATGCAGAATTTGATAGCCGGTCCTTTCTCT-
GCAACAGCAACGCTGGTTGCATCATATTCGTAA, or

ATGATTCGTTTTATCATTATTTATATCGTTGCTTCTGACATCGGTCGCT-
15 GTACTGGCTGATGTGCAGATTAACATCAGGGGGAATGTTTATATCCCC-
CCATGCACCATTAATAACGGGCAGAATATTGTTGTTGATTTTGGGAAT-
ATTAATCCTGAGCACGTGGACAACCTCACGTGGTGAAGTCACAAAAACC-
ATAAGCATATCCTGTCCGTATAAGAGTGGCTCTCTCTGGATAAAAAGTT-
ACGGGAAATACTATGGGAGGAGGTCAGAATAATGTACTGGCAACAAAT-
20 ATAACTCATTTTGGTATAGCGCTGTATCAGGGAAAAGGAATGTCAACAC-
CTTATATTAGGTAATGGTTCAGGAAATGGTTACGGAGTGACAGCAGGT-
CTGGACACAGCACGTTCAACGTTACCTTTACTTCAGTGCCCTTTTCGT-
AATGGCAGCGGGATACTGAATGGCGGGGATTTCCAGACCACGGCCAGTA-
TGAGCATGATTTATAACTGA, or

25 ATGAAAAAATGGTTCCTTGCTTTTTTATTTTTATCCCTGTCAGGCGGT-
AATGATGCTTTAGCTGGATGGCACAATGTCATGTTTTATGCTTTTAAAC-
GACTATTTAACTACAAATGCTGGTAATGTAAAGGTTATTGACCAACCT-
CAGCTATATATACCCTGGAATACAGGCTCTGCTACAGCAACTTATTAT-
TCGTGCTCAGGTCCGGAATTTGCGAGTGGAGTGTATTTTCAGGAGTAT-
30 CTGGCCTGGATGGTTGTTCTAAACATGTCTATACTAATGAGGGGTTT-
AATATATTTCTTGATGTTTCAGAGCAAATATGGTTGGTCTATGGAGAAT-
GAAAATGACAAAGATTTTACTTCTTTGTTAATGGTTATGAATGGGAT-
ACATGGACAAATAATGGTGCCCGTATATGTTTCTATCCTGGAAATATG-
AAGCAGTTGAACAATAAATTTAATGATTTAGTATTCAGGGTTCTTTTG-

CCAGTAGATCTCCCCAAGGGACATTATAATTTTCCTGTGAGATATATA-
 CGTGGAATACAGCACCATTACTATGATCTCTGGCAGGATCATTATAAA-
 ATGCCTTACGATCAGATTAAGCAGCTACCTGCCACTAATACATTGATG-
 TTATCATTCGATAATGTTGGGGGATGCCAGCCGTCAACACAAGTACTT-
 5 AATATAGACCATGGGAGTATTGTGATTGATCGTGCTAACGGAAATATT-
 GCAAGTCAGACGCTTTCAATTTATTGCGATGTACCAGTTAGTGTA-
 ATATCTCTGCTCAGAAATACACCACCAATATACAATAATAATAAATTT-
 TCGGTTGGGTTAGGTAATGGCTGGGATTGATAATATCTCTTGATGGG-
 GTTGAACAGAGTGAGGAAATATTACGCTGGTACACAGCCGGCTCAAAA-
 10 ACAGTAAAGATTGAGAGCAGGTTGTATGGTGAAGAGGGAAAGAGAAAA-
 CCCGGGGAGCTATCTTGGTTCTATGACTAGTGTTCTGAGTTTCCCCTGA

or any subsequence thereof which, when expressed, constitutes an immunogenically active subsequence of the adhesin polypeptide encoded by any one of the entire DNA sequences shown above.

- 15 The sequence of the respective DNA fragments has been established by well-known methods as described in Example 4.

In a further, important aspect, the invention relates to a method of preparing an antigen comprising, as its major immunizing component, a determinant of an adhesin polypeptide, in which a bacterial host
 20 harbouring a hybrid vector containing an inserted DNA fragment which comprises at least the nucleotide type sequence encoding an antigen as defined above, the DNA fragment encoding substantially no other antigen, is cultivated, and the product expressed from the DNA fragment is recovered, optionally followed by purification.

- 25 The DNA fragment which encodes an adhesin polypeptide or an immunogenically active subsequence thereof or a precursor therefor which is convertible to an immunologically active form may be obtained, e.g., by excising the same from the bacterial DNA in which it occurs in nature by recombinant DNA technology, e.g. as follows:

- 30 Chromosomal DNA from an adhesin-polypeptide generating bacterium is cut up using restriction endonuclease, and the individual DNA fragments are religated with suitable vectors which are then transformed

to suitable bacterial hosts. Clones of bacteria that have received the vector are then examined with respect to their adhesin function as assessed by their ability to bind to any solid surface containing the specific receptor, for example by agglutination test with erythrocytes

5 by standard methods. The DNA fragments from the clones which have retained the adhesin function are then subcloned in a suitable vector and then subjected to transposon mutagenesis and/or partial digestion and religation, thereby establishing subclones which contain the smallest DNA fragments which retain the capability of encoding the

10 adhesin function in the bacterial host. Hereby one obtains the smallest necessary piece of DNA operon to express the cell surface adhesin function. Further, manipulations by either transposon mutagenesis or deletion utilizing recombinant DNA technology is used to identify individual genes within the operon which retain or do not retain the

15 capability of expressing the adhesin polypeptide. Gene or genes expressing adhesin polypeptide are then inserted in a suitable vector, optionally with insertion of suitable promoters to enhance the expression of the adhesin polypeptide or polypeptides. Then, the vector is transformed into a suitable host organism, such as a bacterium, e.g.

20 a gram-negative bacterium such as *E. coli* or *B. subtilis*. Another strategy in the last stage is to selectively block or eliminate genes not essential to the adhesin polypeptide production, in the case of *E. coli*, the *papA* and *papC* genes in the above-mentioned smallest necessary piece of DNA operon.

25 As purification by classical chemical methods of the minor pilus adhesin polypeptide from a preparation in which it is present in admixture with the major pilus structural component (which is normally produced from the same operon) is extremely difficult, if not impossible, due to the fact that the structural component, which is immunogenic *per se*,

30 is present in much larger amount, this recombinant DNA technique for producing the minor pilus adhesin polypeptide is of decisive importance to obtain an immunogenically effective and sufficiently pure antigen for the purposes of the present invention, as the recombinant DNA technique permits the selective removal of genes encoding undesired antigens, or expressed in another manner, permits selection of

35 the gene or genes encoding the desired minor adhesin polypeptides. By inserting this gene or these genes in suitable vectors, optionally

fused with other genes as described herein, it is possible to obtain large amounts of the minor pilus adhesin polypeptides which are otherwise present only in immunogenically substantially ineffective, hitherto neglected small proportions in the known pilus preparations.

- 5 In accordance with a special embodiment, several genes encoding one or several of the desired adhesin polypeptides may be inserted in the same vector, so that the resulting product produced by the microor-
ganism will be a product with recurring determinants of the antigen
in question, thus enhancing the immunogenicity or receptor-binding
10 efficiency.

All of these operations are carried out in accordance with methods well known in the field of recombinant DNA technology and explained in more detail in Examples 1-3 below. The vector used in this method may be any vector usually employed for the purpose such as pBR322
15 derivatives, *lacUV5* promoter vectors, broad host range vectors such as *Tac* promoter vectors, shuttle vectors, runaway plasmid derivatives, etc. The growth medium in which the bacterial host is grown may be any growth medium conventionally employed for fermentation processes such as e.g. L-broth or M9 glycerol medium. The bacterial
20 host is conveniently selected among hosts whose behaviour under fermentation conditions is known, such as *Escherichia coli* or *Bacillus subtilis*.

Purification which, as mentioned above, will be advantageous in many cases as the formation of irrelevant antibodies, i.e. antibodies which
25 take no part in the immunization against the antigen in question, and which may even give rise to undesirable reactions on the part of the animal in which it is formed, is avoided as is the administration concurrently with the antigen of possible toxic substances formed by the host bacterium, e.g. a lipopolysaccharide, has, however, been found
30 to be problematic. In order to facilitate purification, a method has been devised involving the use of fused polypeptides. In this method, a DNA fragment encoding a first polypeptide comprising the adhesin polypeptide or an immunogenically active subsequence thereof or a precursor therefor which is convertible to an immunologically active

form is fused to a DNA sequence encoding a second polypeptide, the fused DNA sequence is inserted into a suitable bacterial host, the host is grown in an appropriate medium, the fused polypeptide is recovered from the culture and purified using an assay involving
5 antibodies raised against the second polypeptide, and the second polypeptide is optionally cleaved off by means of a suitable protease followed by separation of the two polypeptides.

An example of a DNA sequence which may advantageously be employed for this purpose is the *lacZ* gene encoding β -galactosidase, as the
10 expression of this gene product and consequently of the adhesin polypeptide or subsequence thereof or precursor therefor is easy to detect, e.g. by growing the bacterial host on lactose indicator plates and selecting for the positive (Lac^+) colonies.

After purification, the second polypeptide may be cleaved off by
15 means of a protease such as trypsin or chymotrypsin. Desired peptide fragments which only derive from the DNA fragment encoding the first polypeptide to which the gene coding for the second polypeptide has been fused are selected on the basis of their immunogenic activity, e.g. as tested *in vitro*. Separation of the two polypeptides may
20 be performed by standard methods such as by ion exchange chromatography, HPLC reverse phase chromatography or affinity chromatography such as immunoaffinity chromatography or receptor affinity chromatography. In the case of immunoaffinity chromatography, either
25 the antibodies raised against the antigens of the invention (comprising the first polypeptide) or the antibodies raised against the second polypeptide may be employed as the antibodies immobilized in the column. In receptor affinity chromatography, the receptor for the adhesin produced may be similarly employed. The DNA fragment used
30 for the fusion with the DNA sequence encoding the second polypeptide may be any of the DNA fragments indicated above.

In an alternative method of preparing the antigen of the invention, the adhesin polypeptide such as the pilus adhesin polypeptide or immunogenically active subsequence thereof may be prepared by peptide synthesis according to well-known methods such as by liquid

phase peptide synthesis or by solid phase peptide synthesis (cf. for instance Stewart and Young, *Solid Phase Peptide Synthesis*, Freeman & Co., San Francisco, USA, 1969). Solid phase peptide synthesis is the preferred method. In solid phase peptide synthesis, the amino acid sequence is built by coupling an initial amino acid to a carrier and then sequentially adding the other amino acids in the sequence by peptide bonding, in this case to a length of at least 5 amino acids. When preparing the adhesin polypeptide or subsequence thereof by solid phase peptide synthesis, it may therefore be advantageous to use the physiologically acceptable polymer useful as carrier for the antigen in the vaccine as the carrier to which the initial amino acid in the sequence is coupled. The preparation of synthetic peptides for use as vaccines may otherwise be performed essentially as described in Shinnick, "Synthetic peptides, immunogens and vaccines", *Ann. Rev. Microbiol.* 37, 1983, pp. 425-446.

According to the invention, the antibody raised against, or directed substantially against, an antigen which comprises a determinant of an adhesin polypeptide or an immunogenically active subsequence thereof or a precursor therefor which is convertible to an immunologically active form may be used in a composition for the passive immunization of a mammalian subject against diseases caused by pathogenic bacteria which adhere to mammalian tissue, which comprises an immunologically effective amount of an antibody as defined above, optionally bound to a suitable carrier, together with an immunologically acceptable vehicle. This composition may be prepared by a method comprising combining an immunogenically effective amount of the antibody with the immunologically acceptable vehicle, e.g. by mixing the components.

The carrier to which the antibody is optionally covalently bound may be any of the carriers mentioned above in connection with the description of the vaccine. The vehicle with which the antibody is mixed may be any vehicle usually employed for this purpose, such as a diluent, suspending agent, adjuvant, etc., added in an amount to give the desired concentration of antibody in the composition.

Though less efficient for immunization than the antigen described above, the antibody may thus be used for immunization purposes, but its principal use is as a diagnostic agent for the diagnosis of infectious diseases caused by pathogenic adhesin-forming bacteria which

5 adhere to mammalian, e.g. human, tissue, examples of which are uropathogenic or enteropathogenic strains of *Escherichia coli* or other enteric bacteria or oral bacteria, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Neisseria catarrhalis*, *Yersinia* spp., *Pseudomonas aeruginosa* or other *Pseudomonas* spp., *Moraxella bovis* or other *Moraxella*

10 spp., *Bacteroides nodosus*, *Staphylococcus* spp., *Streptococcus* spp., or *Bordetella* spp. such as *Bordetella pertussis*. The invention therefore also relates to a diagnostic agent which comprises an antibody as described above, such as an antibody raised against an immunogenic determinant of a pilus adhesin polypeptide, or an antibody raised

15 against an immunogenic determinant of an antigen which is not an adhesin polypeptide or a subsequence thereof or precursor thereof. This antigen may for instance be another polypeptide encoded by an adhesin gene cluster (a sequence of genes which are somehow involved in mediating the adhesion capacity of the bacteria carrying

20 them), for instance one of the other polypeptides involved in the formation of pili, in the case of the pilus polypeptides from uropathogenic *E. coli*, e.g. the gene products of the genes *papB*, *papC* or *papD* (as shown in Fig. 1 and/or Fig. 2) encoding polypeptides of 13 kd, 81 kd and 28.5 kd, respectively. The *papC* and *papD* gene

25 products are at present believed to mediate the assembly and/or anchorage of pilin subunits (encoded by the gene *papA*) during the pilin secretion and polymerization process (for the formation of pili).

When used as diagnostic agents, the antibodies may be labelled with, for instance, a colouring agent so that bacteria containing the antigen

30 to be detected appear as coloured agglomerates in the diagnostic test. Other standard methods such as enzyme-linked immunosorbent assay (ELISA; cf. Materials and Methods) or radioimmunoassay (RIA) using radiolabelled antibodies may also be employed.

Alternatively, the diagnostic agent may comprise a stable, labelled

35 DNA sequence which is at least about 60% homologous with a DNA

- sequence in the bacterium whose presence or absence is to be established by the diagnostic test. In the present context, the term "stable" is intended to indicate that the nucleotide sequence is relatively constant, i.e. that base pair substitutions in which one base pair is replaced by another are reasonably infrequent. In many genes, such base pair substitutions are relatively common without necessarily affecting the amino acid composition of the gene products which are expressed from them, but the base pair substitutions affect the diagnostic process which relies on a fairly high degree of homology between the DNA from the probe and the bacterial DNA used as the specimen to be tested, as the DNA (sub)sequence of the probe recognizes the same sequence or one which resembles it rather closely in the bacterial DNA. In the diagnostic process, probe DNA is labeled, and the DNA is denatured to separate the strands in both the probe and the bacterial DNA; after mixing the DNAs, the strands are left to reform the double helical structure, but in case of homology (DNA sequence recognition), some of the probe DNA will have been introduced in the bacterial DNA. This technique is known as hybridization and is described in e.g. Southern, *Methods In Enzymology* 68, 1980, pp. 151-176. In order to have sufficient specificity as a diagnostic agent, the DNA used as the probe should comprise a unique nucleotide sequence and should therefore have a length of at least 12 nucleotides. The probe DNA may advantageously be labelled with a radioactive isotope such as ^3H or ^{14}C in a manner known *per se*.
- The DNA sequence used as probe DNA may be one which comprises a gene which is part of an adhesin gene cluster, but which does not encode the adhesin polypeptide itself, or a diagnostically effective subsequence thereof. This gene may, for instance, be one which codes for a pilus polypeptide produced by a pathogenic pilus-forming bacterium which is not a pilus adhesin polypeptide, or a diagnostically effective subsequence thereof. In the system exemplified herein, the DNA sequence encoding the pilus polypeptide or a subsequence thereof is derived from a uropathogenic strain of *Escherichia coli*. Particularly advantageous diagnostic agents in this system have been found to be the genes *papB*, *papC* and *papD* - due to their genetic stability as defined above - or a diagnostically effective subsequence of any of those genes.

As described above, the antigen according to the invention may be used as a component of a vaccine. Accordingly, this invention also comprises a method of immunizing a mammal such as a human being against diseases caused by pathogenic bacteria which adhere to mammalian, e.g. human, tissue, which comprises administering a vaccine containing an immunogenically effective amount of an antigen as described above, optionally bound to a suitable carrier, or a composition for passive immunization containing an antibody as described above, also optionally bound to a suitable carrier, and an immunologically acceptable vehicle. The administration may be performed in a manner known *per se*, such as by injecting the antigen or antibody in admixture with a suitable injection vehicle such as isotonic saline.

These pathogenic bacteria may be any bacteria which form adhesins or adhesin-like polypeptides, examples of which are uropathogenic or enteropathogenic strains of *Escherichia coli* or other enteric bacteria or oral bacteria, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Neisseria catarrhalis*, *Yersinia* spp., *Pseudomonas aeruginosa* or other *Pseudomonas* spp., *Moraxella bovis* or other *Moraxella* spp., *Bacteroides nodosus*, *Staphylococcus* spp., *Streptococcus* spp., or *Bordetella* spp. such as *Bordetella pertussis*. An interesting class of such bacteria is constituted by pilus-forming bacteria, important examples of which are uropathogenic or enteropathogenic strains of *Escherichia coli*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Neisseria catarrhalis*, *Moraxella bovis* or other *Moraxella* spp., or *Bordetella pertussis*.

Finally, it is contemplated that the antigen according to the present invention may be employed to determine the presence of the receptor for the particular adhesin polypeptide or active part thereof on mammalian tissue cells such as epithelial cells. This is of potential importance for identifying persons belonging to high-risk groups, i.e. persons who appear to be predisposed for certain kinds of infection as such persons are those who produce large amounts of the receptor to which the pathogenic bacteria causing the infection in question bind by means of the adhesins they produce. When such persons have been identified, prophylactic treatment, i.e. principally immunization/vaccination, may be carried out. The method of determining the

presence of the adhesin receptor and the amounts of adhesin receptor present may comprise incubating a specimen comprising tissue samples or cell scrapings with the adhesin followed by washing. An antibody raised against the adhesin and labelled with, e.g., fluorescence or a radioactive isotope such as I-125, may be incubated with the specimen, or alternatively the thus labelled adhesin may be used directly in the test. The amount of adhesin receptor in the specimen may then be determined by measuring the amount of radioactivity or fluorescence in the specimen in a manner known *per se*.

10. Specifically, it is contemplated that the adhesin polypeptides of a uropathogenic strain of *E. coli*, the amino acid sequences of which are given above, may be used to thus identify women who produce larger amounts of the globoside receptor in their urinary tract and who are therefore assumed to be predisposed for urinary tract infections.

15 This aspect of the invention can be expressed generally as a method of determining receptor density or distribution in a host mammal such as a human, comprising treating a tissue sample from the host with a receptor-specific polypeptide, removing unbound receptor-specific polypeptide and determining the amount of receptor-specific polypeptide bound. The determination of the amount of polypeptide bound may either be made by labelling the polypeptide or by incubating the specimen with a labelled antibody, such as described above.

This method of the invention is very advantageous compared to previous methods where the receptor density or receptor distribution was determined by means of an antibody which was directed against the specific receptors, the reason being that the receptor-specific polypeptide, exemplified by the adhesin polypeptide, can bind to the specific receptor, whether the receptor itself, which is usually one or two sugars, is at the end of a chain of sugars or whether the system of two sugars is somewhere in the middle of the chain, whereas the antibody will only recognize two sugars at the end of the chain, but not the sugars in the middle. Therefore, the binding repertoire of the antibody is limited as compared with the adhesin polypeptide and any attempt to quantify a receptor density will be always underestimated when using antibody for direct combination with the receptors.

Finally, an aspect of the invention relates to a method for preventing or reducing the possibility of infection of a human being or other mammal with a pathogenic adhesin-binding microorganism, the method comprising treating the human being or other mammal with one or more adhesin polypeptides in a suitable method to distribute the polypeptides over the cell surfaces for which infection with a specific pathogenic bacteria is to be prevented, the adhesin polypeptide used being an adhesin polypeptide that will bind with the receptors with which the adhesin generated by the pathogenic bacteria will bind. In this case the adhesin polypeptide is not used as an antigen, but as a direct preventive therapeutic agent to occupy the receptors, thus making it impossible for the pathogenic bacteria to bind to the receptor. In most topical infections, the first step is a specific binding to the specific cell surface of adhesin polypeptide from the specific bacteria, which means that when the receptors are already occupied, the first step in a process to develop an infection cannot take place. With the bacteria being unable to bind, the infection does not occur.

DESCRIPTION OF THE DRAWING

The invention is further described with reference to the drawings in which

Fig. 1 is a map which shows the genetic organization of Pap DNA in pRHU845. The upper line shows the size (in kilobase pairs) of the *EcoRI* fragment inserted in plasmid pACYC184. The positions for various Tn5 insertions are given above. The restriction map of pRHU845 and the positions for identified *pap* genes are given. The thick vertical bar represents the region coding for the signal peptide. The designations under the bars refer to the molecular weights ($\times 10^3$ dalton units) of the mature polypeptides.

Fig. 2 shows the restriction maps and genetic organization of *pap* hybrid plasmids used for *In vitro* mutagenesis. Plasmid pPAP5 carries the entire *EcoRI-BamHI* fragment necessary for expression of Pap pili and digalactoside-specific agglutination of human erythrocytes. Plasmid

pPAP16 carries only the *Sma*I-*Bam*HI fragment under transcriptional control from the *lacUV5* promoter. Plasmid pPAP9 is identical to pPAP16 with the exception that it does not carry the *lacUV5* promoter. Below the horizontal line, Ap^R denotes ampicillin resistance (100 µg/ml).

Fig. 3 shows the whole *pap* region as found in pPAP5 or pPAP22 (top half). pPAP22 is identical to pPAP5 except that it lacks the *Bam*HI-*Pvu*II part of the vector DNA. This plasmid is the parent of the *papA1* derivative pPAP23. Also the position of the *papA1* mutation is shown. The lower part of the figure shows the physical map of the *Sma*I-*Bam*HI region. The positions of the Tn5 insertions in this region are shown. All destroy the capacity to mediate hemagglutination. Below this, the positions of the *papE*, *papF* and *papG* genes are shown. The hatched area represents the putative signal peptides which are believed to be encoded by those genes. Also the positions of the *papE1*, *papF1* and *papG1* mutations are shown. They have been introduced separately into both pPAP5 and pPAP16.

The construction and characterization of the plasmids shown in the drawing are described in Materials and Methods as well as in Examples 1-3.

GENERAL MATERIALS AND METHODS

Chemicals and enzymes

Restriction enzymes and T4 DNA ligase were purchased from Boehringer Mannheim GmbH or New England BioLabs, and used as recommended by the manufacturers. Filling in of 3'-recessive ends was performed by using the Klenow fragment (New England BioLabs) in ligation buffer to which 200 μ M each of the required dNTPs had been added. The *Xho*I linker (5'-CCTCGAGG-3') and *Bam*HI linker (5'-CGGATCCG-3') were obtained from Collaborative Research and 5'-phosphorylated as described by the manufacturers using polynucleotide kinase from New England Biolabs. All chemicals were of the highest purity commercially available. p-erythrocytes were kindly supplied by Dr. B. Cedergran, Blood Bank, University Hospital, Umeå.

15 *Purification of pili*

Pili were purified according to a modification of the method described by Brinton et al., *Immunobiology of Neisseria gonorrhoeae*, Washington DC, USA, 1978, pp. 155-178. Cells were grown for 22 hours at 37°C on five trays (400 x 250 mm) containing L-agar without glucose. The cells were scraped off the trays, suspended in 340 ml ice-cold 5 mM Tris-HCl (pH 8.0) and blended for 10 minutes on ice in a Sorvall Omnimixer at setting 4. After pelletation of the cells and cellular debris (twice for 30 minutes at 20,000 \times g), ammonium sulfate was added to the supernatant to 55% saturation and pili were allowed to precipitate on ice overnight. The precipitate was collected by centrifugation and resuspended in 5 mM Tris (pH 8.0). After dialysis overnight against the same buffer at 4°C, non-dissolved material was removed by centrifugation for 30 minutes at 40,000 \times g. The precipitation-dialysis procedure was repeated an additional three times (precipitation for 3 hours) after which pili were precipitated by adding 0.2 volumes of 1 M $MgCl_2$ -1.5 M NaCl-100 mM Tris-HCl (pH 7.5). The precipitate was dissolved to a protein concentration of 2 mg/ml as measured according to Lowry et al., *J. Biol. Chem.* 193, 1951, pp.

920-929. The yield was about 15 mg for the wild-type and 2-30 mg for the mutants.

Receptor binding assays

For slide agglutination, bacterial cells grown for 22 hours on glucose-free L-agar were suspended to about 10^{11} cells/ml in agglutination buffer (150 mM NaCl 10 mM Tris-HCl pH 7.5) containing 3% heparinized and washed human erythrocytes. The reaction, when positive, was usually apparent within 60 seconds. The positive reaction was a macroscopically visible aggregation of erythrocytes. In the semiquantitative assay, cells grown as above were resuspended to an $A_{600} = 20$. They were then serially 2-fold diluted in 50 μ l agglutination buffer using microtiter plates with conical-bottom wells (Linbro/Titertek, cat. no. 76-321-05, CT, USA). To this was added 10 μ l of a 3% erythrocyte suspension in the same buffer. The dilution in the last well giving a positive agglutination after 2 hours at 4°C was taken as the agglutination titer. The cell count of the original suspension was used together with the titer, to calculate the minimum bacterial concentration required for agglutination.

The agglutination titer of purified pili was determined essentially in the same way as that used for whole cells. When using agglutination buffer, however, the pilus concentration required for agglutination was very high and various attempts were made to increase the sensitivity of the assay. Since pili are negatively charged at physiological pH and aggregate in the presence of 167 mM $MgCl_2$ (see *Purification of pili*), a wild-type pilus preparation was titrated at increasing $MgCl_2$ concentrations, using P_1 -erythrocytes containing the globoside receptor (including the digalactoside), and p-erythrocytes which lack this carbohydrate. The agglutination titer was found to increase 128-fold when the $MgCl_2$ concentration was increased to 100 mM. This was paralleled by an increase of A_{400} of a 200 μ g/ml pilus solution in the same buffers. With $CaCl_2$ and 10-fold higher concentrations of NH_4Cl , the same results are obtained, suggesting that the effect is on pilus-pilus interaction and not on specific receptor binding. In

addition, the agglutination titer of whole pilated cells is not significantly affected by the addition of $MgCl_2$ up to 200 mM. Also the increase in agglutination titer using p-erythrocytes shows that un-specific pilus-erythrocyte aggregation is favoured by the addition of Mg^{2+} ions, although the specificity of the assay (P_1 -titer over p-titer) seems to be unaffected. All titrations of pilus preparations were therefore made in agglutination buffer with 100 mM $MgCl_2$ to give a semiquantitative value for specific agglutination.

Antibody production

10 Preimmune sera were obtained from two healthy 1.8 kg female New Zealand white rabbits by cardiac puncture, filter sterilized and stored at $-20^\circ C$. 75 μg of purified Pap pilli in 1.0 ml of isotonic saline was emulsified with an equal volume of Freund's complete adjuvant and injected in 0.5 ml amounts into four sites, namely subscapularly at two sites and intramuscularly into the two hind legs. After 6 weeks, a booster injection with Freund's complete adjuvant was given. Ten days after the second immunization, the animals were bled by cardiac puncture, and the serum was filter sterilized and stored with 0.02% sodium azide at $-20^\circ C$.

20 *Pilus antigen assay*

For slide agglutination, bacteria were grown and prepared as described for the hemagglutination assays. Agglutination tests of whole cells were performed with 500-fold diluted (PBS pH 7.5) antiserum raised against purified Pap pilli (cf. above). The positive reaction was determined as a macroscopically visible aggregation of bacteria which appeared within 60 seconds.

Protein expression in minicells

Plasmid pPAP5 and its derivatives were transformed to the minicell-producing strain P678-54 (Adler et al., *Proc. Natl. Acad. Sci. USA* 57, 1967, pp. 321-326). Preparation and labelling of plasmid-containing minicells with [^{35}S]methionine were as described by Thompson and

Achtman, *Mol. Gen. Genet.* 165, 1978, pp. 295-304. The radioactive samples were subjected to SDS-polyacrylamide electrophoresis (cf. below). The gels were subsequently fixed, stained, enhanced (Enhance, New England Nuclear) and autoradiographed. Molecular weight standards (Pharmacia Fine Chemicals, Uppsala, Sweden) and purified pilin were electrophoresed in parallel.

SDS-polyacrylamide gel electrophoresis

Radioactive samples were suspended in 100 μ l of sampling buffer containing 62.5 mM Tris-HCl (pH 6.8), 1% sodium dodecyl sulfate (SDS), 0.5% β -mercaptoethanol, and 10% glycerol. After 5 minutes of boiling, the extracts were electrophoresed in 15% polyacrylamide slab gels containing 0.1% SDS (Laemmli, *Nature* 227, 1970, pp. 680-685. Protein standards with molecular weights ranging from 3,000 to 94,000 were run in parallel. After fixation, staining and destaining (Grundström et al., *J. Bacteriol.* 143, 1980, pp. 1127-1134), the gel was fluorographed by using En³Hance (New England Nuclear Corp., Boston, Massachusetts).

Transposon mutagenesis

Transposon mutagenesis with Tn5 was performed essentially as described by Björk and Olsén, *Acta Chem. Scan. Ser. B* 33, 1979, pp. 591-593, with phage λ cl₈₅₇b221 rex::Tn5.

Cell extracts

Cells of strain P678-54 containing various hybrid plasmids were grown on tryptic soy agar in the presence of the appropriate antibiotics. Bacteria were harvested after overnight growth at 37°C suspended in PBS (pH 7.2)-Brij®-35 to a cell density of 1.5 absorbance units at 560 nm, and collected by centrifugation (12,000 x g for 10 minutes). The cell pellet was next suspended in 400 μ l of 1% Nonidet P-40-1% sodium deoxycholate-0.1% SDS-0.15 M NaCl-0.01 M Tris-HCl (pH 7.2) containing lysozyme at 1 mg/ml and was incubated for 10 minutes at 4°C (26). A 400 μ l sample of a 1/15,000 dilution of Pap antisera was

added to the cell extract. After incubation at 4°C for 16 hours, the cell extract antibody mixture was clarified by centrifugation (12,000 x g for 10 minutes).

Competitive enzyme-linked Immunosorbent assay (ELISA)

- 5 Disposable microtiter hemagglutination plates (Cooke polystyrene, 96 U wells) were exposed to 100 µl of a 1 µg/ml solution of purified Pap pili per well in 0.1 M sodium carbonate buffer (pH 9.6) for 16 hours at 25°C. The wells were washed three times with 0.15 M NaCl containing 0.05% (vol/vol) Brij®-35 (Sigma) to remove unbound pili.
- 10 Anti-Pap pilus rabbit antiserum was diluted in PBS (pH 7.2) with 0.05% (vol/vol) Brij®-35 to a concentration which resulted in 50% maximal binding (1/30,000 dilution) and was then mixed with serial dilutions in PBS-Brij® lysates of whole bacteria, cell-free extracts, or Pap pili (positive control), or without added pili (negative control).
- 15 After incubation for 16 hours at 4°C, 100 µl samples were transferred to the sensitized microtiter wells. The plates were incubated for 3 hours at 37°C and were then washed three times with NaCl-Brij®. Alkaline phosphatase-conjugated goat anti-rabbit immunoglobulin G diluted 1/1,000 in PBS-Brij® was added to all wells and incubated for
- 20 1 hour at 37°C. The plates were washed three times with PBS-Brij®, and 1 mg of p-nitrophenylphosphate (Sigma) per ml in 1.0 M di-ethanolamine buffer (pH 9.8) was added to each well and incubated for 20 minutes at 37°C. The reaction was stopped by the addition of 2 N NaOH, and absorbance at 405 nm was determined with an MR
- 25 580 MicroELISA autoreader (Dynatech 011-960-0000; Dynatech Laboratories, Alexandria, Virginia).

Immunoprecipitation

- Immunoprecipitation of [³⁵S]methionine-labelled, plasmid-encoded proteins was performed essentially as described by Dallas and Falkow,
- 30 *Nature* 277, 1979, pp. 406-407, with the exception that pure *Staphylococcus aureus* Protein A bound to Sepharose® was used instead of *Staphylococcus aureus* cells.

Western blotting

Western blotting after SDS-polyacrylamide gel electrophoresis of purified pili was performed as described by Swanson et al., *Infect. Immun.* 38, 1982, pp. 668-672. Diluted Pap antiserum raised against
5 pili purified from strain P678-54 harbouring plasmid pRHU845 (enzyme-linked immune sorbent assay titer, 1:1,000) was used.

Construction of plasmid derivatives

The 9.6 kb long *EcoRI-BamHI* fragment of pRHU30, containing all the genes necessary for the expression of Pap pili and digalactoside-specific binding, was cloned into *EcoRI*- and *BamHI*-digested pBR322
10 (Bolivar et al., *Gene* 2, 1977, pp. 95-113) giving pPAP5 (cf. Fig. 2). To construct a derivative lacking the *PvuII* site in the pBR322 part of the molecule, the vector was *PvuII* digested and ligated to a 20-fold excess of *BamHI* linker. This DNA was subsequently cut with *EcoRI*
15 and *BamHI*, and the largest fragment carrying nucleotides 2065-4360 of pBR322 (Sutcliffe, *DNA: Replication and Recombination* 43, Cold Spring Harbor Laboratory Press, New York, 1978, pp. 77-90) was isolated from a 0.7% agarose gel. This fragment, ligated to the *EcoRI-BamHI* from pRHU30, was transformed (Mandel and Higa, *J. Mol. Biol.*
20 53, 1970, 159-162) into *E. coli* strain HB101 (Boyer and Roulland-Dussoix, *J. Mol. Biol.* 41, 1969, pp. 459-472). The isolated clone was named pPAP22 and is identical to pPAP5 except that the clone lacks the *BamHI-PvuII* segment. A derivative, pPAP23, carrying a frame-shift mutation at the single *PvuII* site in *papA* was constructed by
25 linearizing pPAP22 with *PvuII* and ligating it to a 20-fold excess of *XhoI* linker. After digestion for 3 hours using 20 units of *XhoI*/µg of DNA, the fragment was purified on a Sephadex® G150 column (Pharmacia Fine Chemicals, Uppsala, Sweden) equilibrated with 10 mM Tris-HCl pH 8.0 and 1 mM EDTA. After ligation and transformation
30 into *E. coli* strain HB101, DNA from six clones was isolated (Birnboim and Doly, *Nucleic Acids Res.* 7, 1979, pp.1513-1523) and analyzed. Five of the clones had a new *XhoI* site at the former *PvuII* site and one of these was called pPAP23 and used in further studies.

The following manipulations were done to construct plasmid pPAP16 (Fig. 2) and derivatives of both this plasmid and pPAP5 with mutations in the *Sma*₁-*Bam*HI region. Plasmid pPAP1 was constructed by linearizing 2 µg of pBR322 with *Cla*I, and blunt ends were created using 5 units of Klenow fragment and 200 µM each of dGTP and dCTP (15 minutes at 30°C in ligation buffer). This DNA was, after heat inactivation of the enzyme, ligated to the gel-purified *Sma*₁-*Sma*₂ fragment of pPAP5 (Fig. 2), and by screening small-scale plasmid preparations, a plasmid carrying the fragment in the same orientation relative to the vector as on pPAP5, was isolated. The clone pPAP1 expressed the last polypeptide (35 kd) in a slightly truncated form. Thus the gene for this polypeptide extends beyond the *Sma*₂ site and is present in a truncated form in pPAP1. This mutation was isolated on a *Kpn*I-*Bam*HI fragment which was ligated into pPAP5 cut with these enzymes. The derivative, pPAP7 obtained in this way thus contains *pap* DNA up to the *Sma*₂ site. Plasmid pPAP9, containing the whole *Sma*₁-*Bam*HI region was constructed by ligating the *Kpn*I-*Bam*HI fragment of pPAP5 in excess to *Kpn*I-*Bam*HI digested pPAP1. To make frameshift mutations in the insert of pPAP9, this plasmid was partially digested with *Hinc*II in the presence of 150 µg/ml ethidium bromide (Greenfield et al., *Biochim. Biophys. Acta* 407, 1975, pp. 365-375). Linearized plasmid was then isolated from a 0.7% agarose gel and ligated to an excess of *Xho*I linkers. After *Xho*I digestion, Sephadex® G150 gel chromatography, and ligation, the DNA was transformed into *E. coli* strain HB101, selecting for ampicillin resistance. The DNA purified from 23 clones was analyzed by digestion with *Xho*I and *Sal*I. Of 15 mutants within the insert, 13 were linker insertions at *Hinc*II₂ and two at the *Hinc*II₁ site. No mutants at *Hinc*II₃ were obtained. pPAP5 derivatives carrying these mutations were constructed in a way analogous to pPAP7. These plasmids were named pPAP15 (*Hinc*II₁) and pPAP14 (*Hinc*II₂). pPAP19 was constructed by deleting the *Xho*I-*Sal*I fragment of pPAP14 by re-ligating an *Xho*I-*Sal*I digest of the latter plasmid. The construction of pPAP20 from pPAP15 was done in the same manner. To make plasmid pPAP26 (*papA1*, *papE1* double mutant), the large *Kpn*I-*Bam*HI fragment of pPAP23 (*papA1*) was ligated to the small *Kpn*I-*Bam*HI fragment of pPAP10 (*papE1*).

Plasmid pPAP9 did not complement Tn5 insertions within the *Sma*I-*Bam*HI region. This was suspected to be due to insufficient transcription over the insert. Therefore the *Eco*RI fragment containing the *lac*UV5 promoter was isolated from pSKS106 (Casabadan et al., *Methods Enzymol.* 100, 1983, pp. 293-308), and ligated in excess to *Eco*RI linearized pPAP9. A clone with the fragment in the correct orientation, pPAP16, was subsequently isolated by screening DNA preparations using *Pst*I digestion since the promoter fragment carries an asymmetrically placed site for this enzyme. The same procedure was applied to the other pPAP9 derivatives resulting in pPAP4 (*Sma*I₂-*Bam*HI deletion), pPAP18 (*Hinc*II₁ mutation) and pPAP17 (*Hinc*II₂ mutation).

EXAMPLE 1

Cloning and Identification of the gene for the major pilus subunit

- 15 High molecular weight chromosomal DNA from a spontaneously Lac⁻ derivative of a uropathogenic isolate of *E. coli* J96 (cf. R. Hull et al., *Infect. Immun.* 33, 1981, pp. 933-938; mannose-resistant hemagglutination (MHRA⁺) and digalactoside-specific binding) was isolated according to standard methods. This DNA was subsequently partially
20 digested with the restriction endonuclease *Sau*3A. The restriction fragments were ligated to the plasmid vector pHC79 (Collins, *Methods Enzymol.* 68, 1979, pp. 309-326) which had previously been linearized with the restriction endonuclease *Bam*HI. This DNA was *in vitro* packaged into λ phage particles according to the procedure described
25 by B. Holm, *Methods In Enzymology* 68, 1979, pp. 1127-1134. These particles were used to infect *E. coli* strain P678-54 (Adler et al., *op. cit.*). The bacteria were then spread on plates containing ampicillin leading to the formation of colonies containing the recombinant plasmid which is ampicillin-resistant.
- 30 Individual colonies were screened for agglutination of human erythrocytes in the presence of 1% of mannose, and the clone (pRHU807) causing mannose-resistant hemagglutination was selected. Subclones

(pRHU30 and pRHU845) of pRHU807 were constructed retaining MRHA⁺ as described by R. Hull et al., *op. cit.* The presence of both of these subclones in *E. coli* strain HB101 also causes the formation of pill. The hemagglutination caused by *E. coli* strain HB101 containing
5 pRHU845 was totally inhibited by the presence of soluble digalactoside, both in the presence and in the absence of mannose, thus demonstrating that in this case the MRHA⁺ phenotype expressed by this strain is identical to digalactoside-specific binding.

The structural gene for the major polypeptide forming the Pap (pill associated with pyelonephritis) pilus (*papA*) was identified by Western blotting and immunoprecipitation from subclones and mapped to about
10 2.2 kb as shown in Fig. 1. The position of the *papA* gene was confirmed by the identity between the amino acid sequence of the gene product inferred from the DNA sequence (M. Båga et al., *J. Bacteriol.* 157, Jan. 1984, pp. 330-333) comparing it with the N-terminal
15 sequence of the major Pap pilus subunit (cf. O'Hanley et al., *J. Exp. Med.* 158, Nov. 1983, pp. 1713-1719).

EXAMPLE 2

Identification of the pilus DNA sequence

20 To characterize the genes required for Pap pilus formation and digalactoside-specific agglutination, subclones of pRHU845 and transposon Tn5 insertion mutants were constructed and analyzed as described in Normark et al., *Infect. Immun.* 41, Sept. 1983, pp. 942-949. By further analysis of the Tn5 insertion mutants and subclones,
25 it was shown that only the DNA residing between position about 1.0 and about 9.4 kb from the left-hand *EcoRI* site (cf. Fig. 1) was necessary to code for Pap pilus formation and digalactoside-specific binding. Insertional mutants between 7.9 and 9.2 kb from the *EcoRI* site (cf. Fig. 1) abolished digalactoside-specific binding without
30 inhibiting the formation of Pap pill.

EXAMPLE 3

Genetic characterization of pilus adhesin DNA

The region identified in Example 2 as necessary for Pap pilus formation and digalactoside-specific binding was recloned as a 9.6 kb long
5 *EcoRI-BamHI* fragment of pRHU30 into pBR322 giving plasmids pPAP5 (see Fig. 2) and pPAP22, as described in Materials and Methods. Both pPAP5 and pPAP22 carry the entire *EcoRI-BamHI* insert, although pPAP22, due to a deletion in vector DNA, has a unique *PvuII* site in the *papA* structural gene. Plasmid pPAP23 with a frameshift mutation,
10 *papA1*, was constructed by introducing an 8 bp long *XhoI* linker in the unique *PvuII* site in pPAP22 (cf. Fig. 3). In *E. coli* strain HB101, this frameshift mutant, unlike the wild-type, was not agglutinated by antiserum raised against purified Pap pili.

E. coli strain HB101 harbouring pPAP23 agglutinates human P₁-erythrocytes as well as digalactoside-coated latex beads. Hence, pPAP23/-
15 HB101 appears to express the same receptor binding specificity as HB101 carrying the wild-type *pap* operon on pPAP22 or pPAP5. Thus, inactivation of the pilin gene *papA* did not diminish the degree of digalactoside-specific agglutination in the assay employed.

20 Tn5 insertions in the distal part of *pap* DNA abolish hemagglutination but allow Pap pili to be formed. It was thus assumed that the genes mediating agglutination would be located in this region. To further investigate the importance of the polypeptides encoded here, the *SmaI₁-BamHI* fragment, shown in Fig. 2, was subcloned into pBR322
25 (see Materials and Methods). Since the resulting plasmid did not complement Tn5 insertions in the *SmaI₁-BamHI* region, the cloned fragment was put under the transcriptional control of the *lacUV5* promoter (in order to ensure adequate transcription of the genes on the fragment) which was inserted into the plasmid as an *EcoRI* fragment
30 derived from pSKS106 (see Materials and Methods). This construct, pPAP16 (cf. Fig. 2), complemented the four non-hemagglutinating Tn5 mutants with insertion points in the *SmaI₁-BamHI* fragment. The localisation of these mutants is shown in Fig. 3.

To further define the genes on the *Sma*₁-*Bam*HI fragment, a detailed restriction map of the pPAP16 insert was constructed with an accurate localisation of relevant Tn5 Insertions (cf. Fig. 3). Three frameshift mutational derivatives of pPAP5 containing lesions in this region (cf. Fig. 3 and Materials and Methods) were also constructed. Two mutant plasmids, pPAP14 and pPAP15, carry *Xho*I linkers in the *Hinc*II₂ and *Hinc*II₁ sites, respectively. In a third mutant, pPAP7, *pap* DNA from *Sma*₂ to *Bam*HI (cf. Fig. 3) had been deleted.

The polypeptides expressed from pPAP5 and its three mutant derivatives were [³⁵S]methionine labelled in *E. coli* minicells, and the polypeptides expressed were analysed on a SDS-polyacrylamide gel. When compared with pPAP5, plasmid pPAP7 did not express the 35 kd polypeptide. Instead, a new polypeptide of 34 kd appeared. Since the mutation in pPAP7 truncated the *pap* region at the *Sma*₂ site this would map the 3' end of the gene coding for the 35 kd polypeptide, *papG*, between the *Sma*₂ and the *Bam*HI sites (cf. Fig. 3). This is the last gene in the *pap* region.

The *Hinc*II₂ mutation in pPAP14 abolished expression of the 15 kd polypeptide, as do Tn5 insertions 002 and 021, which accurately maps the gene *papF* as encoding this polypeptide (cf. Fig. 3). No other polypeptides were affected by the *Hinc*II₂ mutation (*papF*) in pPAP14. The minicell preparation of the *Hinc*II₁ linker insertion mutant, pPAP15, does not produce the 16.5 kd polypeptide. The gene for this polypeptide is termed *papE* and the frameshift mutation is referred to as *papE1*. The truncation of the *papG* gene products by the *Sma*₂-*Bam*HI deletion shows that this gene is transcribed from left to right in Fig. 3. Polarity effects exerted by Tn5 insertions in *papE* and *papF* on *papG* show that the transcription of all three genes is in this direction.

To confirm the position of the Tn5 mutations relative to the *papF* and *papG* genes, the Tn5 mutations 002, 021, 026 and 042 (cf. Fig. 3) were complemented with the mutated *Sma*₁-*Bam*HI region. For this purpose, *papE1*, *papF1* and *papG1* derivatives of pPAP16 carrying the *Sma*₁-*Bam*HI region under *lacUV5* promoter control were constructed as described in Materials and Methods. These were then transformed

- to *E. coli* strain HB101 carrying the Tn5 derivatives of pRHU845 (Normark et al., *op. cit.*) and assayed for globoside-specific hemagglutination using P₁- and p-erythrocytes. The *papE1* derivative complemented all Tn5 mutations as did the parent plasmid pPAP16.
- 5 The *papF1* plasmid complemented Tn5 mutations 026 and 042, while the plasmid carrying *papG1* complemented mutations 002 and 021. This defines the 002 and 021 Tn5 insertions as mutations in *papF* and shows that Tn5 insertions 026 and 042 reside in the *papG* gene. It also clearly shows that *papF* and *papG* are separate, independently
- 10 *trans*-complementable genes. The genetic map of this region (shown in Fig. 3) was constructed on the basis of these data.

- As indicated above, Tn5 insertions in *papF* and *papG* abolish hemagglutination completely, though pili are formed. To assess the individual importance for hemagglutination of the *papE*, *papF* and *papG*
- 15 gene products, the non-polar linker insertion mutant derivatives of pPAP5 in hemagglutination tests. It was found that neither the *papF1* nor the *papG1* derivative showed any agglutination of P₁-erythrocytes, demonstrating that both the *papF* and the *papG* gene products are needed for agglutination. The *papE1* mutant did not by itself
- 20 affect the hemagglutination titer, but surprisingly a *papA1,papE1* double mutant, pPAP26, did not agglutinate P₁-erythrocytes when transformed to *E. coli* strain HB101.

- The pilus antigen formation and digalactoside-specific binding properties of the various mutant derivatives of pPAP5 or pPAP22 in *E. coli*
- 25 strain HB101 are summarized in Table I.

Table I
Characteristics of plasmids used for mapping
and functional analyses of *papA*, *papE*, *papF* and *papG*

5	Plasmid	Relevant genotype	Phenotype	
			Pilus-antigen	Hemagglutination
	pSN002	<i>papF</i> ::Tn5-002	+	-
	pSN021	<i>papF</i> ::Tn5-021	+	-
10	pSN026	<i>papG</i> ::Tn5-026	+	-
	pSN042	<i>papG</i> ::Tn5-042	+	-
	pPAP5	wild-type	+	+
	pPAP15	<i>papE1</i>	+	+
	pPAP14	<i>papF1</i>	+	-
15	pPAP7	<i>papG1</i>	+	-
	pPAP20	<i>papE1</i> , Δ <i>papF-G</i>	+	-
	pPAP19	<i>papF1</i> , Δ <i>papG</i>	+	-
	pPAP22	wild-type	+	+
	pPAP23	<i>papA1</i>	-	+
20	pPAP26	<i>papA1</i> , <i>papE1</i>	-	-
	pPAP9	Δ <i>papB-D</i>	-	-
	pPAP1	Δ <i>papB-D</i> , <i>papG1</i>	-	-
	pPAP16	Δ <i>papB-D</i> , <i>lacP</i> _{UV5}	-	-
	pPAP18	Δ <i>papB-D</i> , <i>lacP</i> _{UV5} , <i>papE1</i>	-	-
25	pPAP17	Δ <i>papB-D</i> , <i>lacP</i> _{UV5} , <i>papF1</i>	-	-
	pPAP4	Δ <i>papB-D</i> , <i>lacP</i> _{UV5} , <i>papG1</i>	-	-

pSN plasmids are pACYC184 derivatives (carrying the *EcoRI* fragment from pRHU845; each plasmid contains a different Tn5 insertion as shown in Fig. 1), whereas pPAP plasmids are derivatives of p8R322. Pilus antigen was determined by slide agglutination of a cell suspension with antisera raised against Pap pili.

It appears from the table that mutation *papA1* in pPAP23 completely abolished the formation of the major Pap pilus subunit (the *papA* gene product) without affecting digalactoside-specific binding. Conversely, mutation *papF1* in pPAP14 and *papG1* in pPAP7 abolished digalactoside-specific binding without inhibiting the formation of Pap pili.

Mutations in genes *papC* and *papD* abolished both pilus formation and digalactoside-specific binding. Only mutations in *papF* and *papG* lead to the abolition of the digalactoside-specific binding without preventing the formation of Pap pili. The only exception is the double mutant *papA1-papE1* which is negative for agglutination as described above. Mutations in *papA* or *papE* only are adherent. This effect is assumed to be ascribable to the fact that the *papA* or *papE* polypeptides are (presumably) required to anchor the adhesin to the cell wall. It may therefore be concluded that the *papF* and/or *papG* genes encode the digalactoside-specific adhesion.

EXAMPLE 4

Establishing the DNA sequence of the pilus adhesin DNA

100 µg of pPAP9 (constructed as described in Materials and Methods; shown in Fig. 2) was digested with *EcoRI* and *BamHI* and subjected to preparative agarose gel electrophoresis in order to isolate the *EcoRI-BamHI* fragment containing the *SmaI₁-BamHI* region (cf. Fig. 3).

Aliquots of this fragment were digested with the endonucleases *HaeIII*, *RsaI*, *AluI*, *HpaII*, *Sau3A*, *TaqI*, *HincII* and *BglII* separately or in combination. Fragments obtained were either cloned directly or after preparative agarose gel electrophoresis, and fragment isolation performed into phage M13 vectors (M13mp8 and M13mp9; Messing et al., *Nucleic Acids Res.* 9, 1981, pp. 309-321). The inserts were sequenced using the method of Sanger et al., *Proc. Natl. Acad. Sci. USA* 74, 1977, pp. 5463-5467 (dideoxy sequencing) until unambiguous overlapping readings of the DNA sequence of the *SmaI₁-BamHI* fragment were obtained for both strands.

EXAMPLE 5

Amino acid sequencing of the pilus adhesins

Among the possible reading frames, the genes *papE*, *papF* and *papG* were identified from the known position of the genes established by means of linker and transposon Tn5 insertions (cf. Fig. 3) and the known size of their respective gene products, 16.5 kd, 15 kd and 35 kd, respectively. The N-terminal ends of these genes were identified. The amino acid sequence was derived from the DNA sequence using the genetic code established for *E. coli*. Since all the gene products are made as precursors containing single peptides, the 5'-end of the gene was assumed to be a methionine followed by a signal peptide-like sequence (G. von Heijne, *European Journal of Biochemistry* 133, 1983, pp. 17-21).

EXAMPLE 6

15 *Homology with other uropathogenic E. coli DNA*

Several fragments from the *Sma*₁-*Bam*HI region were isolated and ³²P-labelled by nick translation. The fragments were selected so as to cover the entire region in small segments. These were then used as probes in Southern blots of digests of plasmids pDC5 (Clegg and Pierce, *Infect. Immun.* 42, 1983, pp. 900-906) and pPIL110-35 (van Die et al., *FEMS Microbiol. Letters* 19, 1983, pp. 77-82) under stringent conditions. Strong hybridization signals were obtained with probes from the *papE* and *papF* genes whereas no signals were obtained from the *papG* gene region. Strong hybridization under stringent conditions were also obtained from a probe of the *papC* gene between the *Hpa*I sites at about 3.2-3.4 kb from the *Eco*RI site (cf. Fig. 1).

Detailed restriction maps of pDC5 and pPIL110-35 were constructed and found to be nearly identical with the restriction map of pPAP5 with respect to the *papC* and *papD* regions. A lesser, though still

high degree of similarity was observed for the *papE* and *papF* genes. It may therefore be concluded that the DNA which encodes MRHA⁺ in other uropathogenic strains of *E. coli* is very similar to that cloned in pPAP5 (derived from *E. coli* strain J96) and that results obtained in the Pap system can be generalized to most pyelonephritogenic strains. As regards pPIL110-35, it has also been demonstrated that the MRHA expressed from its DNA is digalactoside-specific. Similar results were obtained with chromosomal DNA from clinical isolates by the present inventors as well as by other researchers (cf. Low et al., *Infect. Immun.* 43, 1984, pp. 353-358).

EXAMPLE 7

Construction of a fusion between the papG gene and the lacZ gene

Plasmid pPAP9 was digested with *Bgl*II and *Sal*I (located about 375 bp to the right of the *Bam*HI site in pPAP9). The resulting fragment was ligated to plasmid pMC874 (Casabadan et al., *J. Bacteriol.* 143, 1980, pp. 971-980) which had previously been digested with *Bam*HI and *Sal*I. After transformation to pMC1061 (Casabadan et al., *op. cit.*) and plating on plates containing 100 µg/ml of ampicillin, recombinants were analyzed. A plasmid, pHMG51, consisting of pPAP9 in which the *Bgl*II-*Sal*I fragment had been replaced by the *lac*-cassette from pMC874 (the *Bam*HI-*Sal*I fragment) was isolated and shown by minicell analysis as described in Materials and Methods to code for a *papG-lacZ* fusion peptide. This result was also expected from the known sequence of the *papG* gene and that of the *lacZ* gene as present in pMC874.

25 INSTRUCTIONS

A. Preparation of other fused genes

In an alternative method to that disclosed in Example 7, N-terminal DNA fragments comprising the *papF* gene are obtained by linearizing pPAP9 with *Bgl*II. This DNA is then incubated for increasing periods

of time with the exonuclease *ExoIII* and then treated with nuclease *S1* resulting in increasing deletions from the *BglII* site. *HindIII* linkers are attached. This DNA is then redigested with *SmaI* and *HindIII* and subjected to preparative agarose gel electrophoresis. Fragments ranging from 1,400 to 1,000 bp (cf. Fig. 3) are isolated and ligated into the appropriate fusion vector which has previously been digested with *SmaI* and *HindIII* as described below.

Fragments containing the *papG* gene are constructed by the method described above, but by digesting with *BamHI* instead of *BglII*. Fragments ranging from 2,400 to 1,500 bp on the gel (cf. Fig. 3) are selected. Fragments containing the *papE* gene are constructed in the same manner, selecting fragments ranging from 800-400 bp (cf. Fig. 3).

DNA fragments encoding the N-terminal portion of the *papF* gene are cloned into a fusion vector such as pSKS104, pSKS105 or pSKS106 (Casadaban et al., *Methods in Enzymology* 100, 1983, pp. 293-308) so as to create gene fusions with the *lacZ* gene. The fused gene in these constructions is transcribed by the *lacUV5* promoter.

This construction is transformed to a strain containing the *LacI^q* gene, e.g. *E. coli* strain JM103 (Messing et al., *Nucleic Acids Res.* 9, 1981, pp. 309-321), selecting for ampicillin resistance. This strain is then grown in a suitable medium such LB-broth (G. Bertani, *J. Bacteriol.* 62, 1951, pp. 293-300) to an optical density of OD₆₀₀ = 0.4. Transcription of the fused gene is then induced by adding IPTG (J. Miller, *Experiments in Molecular Genetics*, Cold Spring Harbor, New York, 1972). Incubation is continued until maximum expression of the fused gene product has been obtained. The cells are then harvested and the fused gene product is purified by standard methods using an assay for β -galactosidase activity (cf. J. Miller, *op. cit.*). The purified fusion product may then be used directly in vaccine tests in e.g. rodents, monkeys or swine.

B. Preparation of a vaccine

The entire *papE*, *papF* or *papG* gene products or appropriate fragments thereof for use as vaccine are prepared in either of the following ways:

- 5 1. The purified fusion proteins of the *lacZ* gene and *papE*, *papF* or *papG* genes are digested with a suitable protease, e.g. trypsin or chymotrypsin, or a chemical reagent such as cyanogen bromide or hydroxyl amine. The desired peptide is obtained from the resulting peptide mixture by standard techniques, e.g. ion exchange chromatography or HPLC reverse phase chromatography.

2. Alternatively, antibodies against the fusion proteins are raised by injecting these into rabbits. The resulting antibodies can be used for the purification of the non-fused, pure *papE*, *papF* or *papG* gene products from a *lacZ*⁻ bacterium containing a plasmid carrying these
15 genes. This plasmid may be a pBR322 derivative such as pPAP5 or pPAP16, or a runaway plasmid derivative such as pBEU28 (Uhlén et al., *Gene* 22, 1983, pp. 255-265).

The purification is performed either by immunoaffinity gel chromatography or the antibody is used to develop an ELISA assay which is
20 used to detect the polypeptides when developing a purification protocol (cf. Materials and Methods).

Fragments of these purified polypeptides may, if desired, be obtained by cleavage with protease etc. as described under 1.

3. Fragments consisting of 5-30 amino acids or more of the *papE*,
25 *papF* and *papG* gene products are synthesized by solid phase peptide synthesis (Stewart and Young, *Solid Phase Peptide Synthesis*, Freeman & Co., San Francisco, USA, 1969). They may then be used for vaccination as such or coupled to a carrier molecule of a physiologically acceptable carrier such as poly-L-lysine or poly-D,L-alanine
30 with or without an adjuvant substantially as described in Arnon, *J. Immunological Methods* 61, 1983, pp. 261-273.

C. The *Pseudomonas* system

Assuming that pilus formation and adhesion are linked in *Pseudomonas* species, chromosomal DNA from an adhering strain of *Pseudomonas* is digested with a restriction endonuclease to produce fragments which
5 are cloned into a pBR322 derivative, a *Pseudomonas/E. coli* shuttle vector, a plasmid vector or a phage vector and transformed/transfected into *E. coli*. The bacteria harbouring the hybrid vector are screened for production of the major *Pseudomonas* pili subunit using antibodies raised against the purified *Pseudomonas* pili. (This has
10 been done for *N. gonorrhea* using pBR322 as a vector; cf. Meyer et al., *Cell* 30, 1982, pp. 45-52).

This clone is then used directly or as a probe to obtain a larger DNA fragment containing the pilin gene. This fragment is then cloned into a *Pseudomonas/E. coli* shuttle vector which is transferred into a
15 non-piliated, non-adhering strain of *Pseudomonas* which is then assayed for adhesion and pilus formation. Mutagenesis of this fragment is then performed in essentially the same way as described in Example 2 with respect to uropathogenic *E. coli* with the exception that the phenotypic assays are carried out in *Pseudomonas* instead.

20 Alternatively, if the chromosomal DNA is cloned directly into a *Pseudomonas* vector or a *Pseudomonas/E. coli* shuttle vector and transformed to a non-adhering strain of *Pseudomonas*, the clones can be screened for adhesion directly. Other assays may be used, for instance binding of the soluble receptor.

25 Fusion proteins and protein production in *E. coli* is performed in similar ways to those described above, though possibly transcription and translation initiation signals must be altered synthetically. Alternatively, protein production may be performed in a homologous system in *Pseudomonas* using e.g. the broad host range *Tac* promoter vectors
30 described by Bagdasarian et al., *Gene* 26, 1983, pp. 273-282. DNA sequencing and amino acid analysis is carried out essentially as described in Examples 4 and 5 above, and on the basis of the sequence analysis, synthetic peptides may be produced as described above.

Similar methods as those described in Examples 1-5 as well as those outlined for *Pseudomonas* may be used to identify and produce putative adhesin polypeptides from other adhering bacteria such as *Neisseria* species, etc.

- 5 In principle, all investigations may be carried out using protein chemistry. The adhesin polypeptides may be enriched/purified by receptor, e.g. digalactoside, affinity chromatography or any other appropriate method (such as antibody affinity chromatography). The purity of the protein may be assayed by SDS-polyacrylamide gel electrophoresis as described in Materials and Methods. To ensure that the adhesins constitute a large fraction of the preparation, equilibrium dialysis experiments with the radioactively labelled receptor may be employed to calculate the number of binding sites per molecule of protein present. This is expected to be between 0.1 and 10 ligands per molecule of protein.
- 10
- 15

EXAMPLE 8

MATERIALS AND METHODS USED IN THIS EXAMPLE

Bacterial strains, plasmids and growth conditions

5 All bacterial strains are *E. coli* K12 derivatives, except the clinical isolates described in Table 2. For protein expression analyses a *recA* derivative of P678-54 (1), AA10 was used. M13 cloning and phage propagation was carried out in JM103. HB101 was the host in all other experiments.

10 Plasmid pPAP5 (cf. General Materials and Methods above) is a pBR322 derivative carrying a 9.5 kb *EcoRI-BamHI* chromosomal fragment isolated from *E. coli* J96. This clone expresses an F⁺CI34.3 pilus antigen which is serologically related to FI2. The gene map of the *pap* cluster is shown in Fig. 1. Plasmid pDC5 is a pACYC184 derivative carrying an 8.0 kb *ClaI-BamHI* fragment of *E. coli* 1A2, whereas
15 pPIL110-35 is a pACYC184 derivative containing a 16 kb *EcoRI* fragment isolated from *E. coli* AD110 responsible for the formation of F₇₂ pilus antigen.

The following concentrations of antibiotics were used for selection:
20 carbenicillin 100 µg/ml, tetracycline 15 µg/ml, kanamycin 20 µg/ml and chloramphenicol 20 µg/ml. Bacteria were grown at 37°C in Luria broth or on Luria agar.

General procedures

The CaCl₂ procedure was used for transformation. Plasmid DNA was isolated by a modification of the alkaline clear lysate procedure of
25 Birnboim H.C. and J. Doly ("A rapid alkaline extraction procedure for screening recombinant plasmid DNA" *Nuclear Acids Res.* 7, 1979, pp. 1513-1523) and Grosveld *et al.* ("Isolation of β-globin-related genes from a human cosmid library", *Gene* 13, 1981, pp. 227-237) followed by two consecutive ethidium bromide/CsCl equilibrium centrifuga-

- gations. Restriction endonucleases were used under the conditions recommended by the manufacturers (New England BioLabs, USA, Boehringer Mannheim GmbH or Bethesda Research Laboratories GmbH). Digested DNA was separated on 0.5% to 1.5% (wt/vol) agarose gels.
- 5 Phage λ DNA and phage ϕ X174 DNA cleaved with *Hind*III and *Hae*III, respectively (New England BioLabs) were used as molecular weight standards. DNA fragments were obtained in pure form by electroelution from 5% (wt/vol) polyacrylamide gels.

Blotting and hybridization procedures

- 10 [32 P]-labelled DNA probes were prepared by nick-translation or by priming DNA synthesis of cloned M13 single stranded DNA templates with an M13 hybridization probe primer (New England BioLabs). [32 P]dGTP (Amersham, England) was incorporated to a specific activity of approximately 1×10^8 cpm/ μ g. Plasmid DNA, size fractionated
- 15 on agarose gels, was transferred to nitrocellulose filters (Schleicher and Schüll, BA85) according to Southern, E.M., "Detection of specific sequences among DNA fragments separated by gel electrophoresis", *J. Mol. Biol.* 98, 1975, pp. 503-517. The blotted filters were prehybridized for 2 hours at 68°C in a hybridization solution consisting of: 4x SSC
- 20 (1xSSC is 150 mM NaCl; 15 mM Na citrate pH 7.0), 10x Denhardt's solution, 0.1% SDS, 2 mM EDTA and sonicated calf thymus DNA at 50 μ g/ml. Radiolabelled probe in fresh hybridization solution (1×10^6 cpm/ml) was then added to the filters which were incubated for 18 hours in plastic bags. For stringent conditions, hybridization was
- 25 performed at 68°C, and washes were conducted at the same temperature in salt concentrations from 2x SSC; 0.1% SDS down to 0.1x SSC; 0.1% SDS. Non-stringent hybridization was carried out under similar conditions, except that the hybridization temperature was 55°C and that washes were done in 2x SSC. Filters were exposed overnight to
- 30 Dupont Cronex 4 X-ray film with an intensifying screen.

Analyses of protein expression in minicells

Plasmids pPAP5, pPAP502, pDC5 and pPIL10-35 were transformed into the minicell producing strain AA10. Preparation and labelling of mini-

- cells with [³⁵S]-methionine (Amersham) was as described by Thompson, R., and M. Achtman, "The control region of the F sex factor DNA transfer cistrons: restriction mapping and DNA cloning", *Mol. Gen. Genet.* 165, 1978, pp. 295-304. The radioactive samples were separated on linear 15% (wt/vol) SDS-polyacrylamide gels. The gels were subsequently fixed, stained, destained, enhanced (Enhance, New England Nuclear GmbH) and exposed to X-ray film for 1-6 days. Molecular weight standards were from Pharmacia Fine Chemicals, Sweden.

Nucleotide sequence determination

- 10 Relevant fragments were cloned into phage M13 cloning vectors M13mp8 and M13mp9 and transformed into *E. coli* strain JM103. Single stranded template DNA was isolated from the phage as described by Messing *et al.* "A system for shotgun DNA sequencing", *Nucleic Acids Res.* 9, 1981, pp. 309-321. The DNA sequences were determined by the dideoxy chain termination method of Sanger *et al.*, "DNA sequencing with chain-terminating inhibitors", *Proc. Natl. Acad. Sci. USA* 74, 1977, pp. 5463-5467, utilizing the M13 pentadecamer sequencing primer (New England Biolabs).

Receptor binding assays

- 20 The binding properties of the gene products encoded by the plasmids listed in Tables 1 and 2 were determined by slide agglutination as described in General Materials and Methods above using P₁-erythrocytes containing the globoside receptor and p-erythrocytes which lack the globoside.

Pilus antigen assay

Slide agglutination, utilizing antisera raised against purified Pap pili (37) were performed as described in General Materials and Methods above. Antiserum was used as a 500-fold dilution in PBS (pH 7.5).

Construction of plasmid derivatives for complementation analyses

Plasmid pPAP43 is a derivative of pPAP5, obtained by *Sma*I digestion followed by ligation at low DNA concentration. This plasmid lacks the *Sma*I₁-*Sma*I₄ region of pPAP5 (Fig. 1) and consequently carries only the genes *papB* and *papA*. In order to construct the cutback derivative pPAP502, plasmid pDC5 (Fig. 1) was completely digested with *Bgl*II, and partially digested with *Bam*HI, followed by religation and transformation into HB101. Plasmid DNA was isolated from the transformants and screened for the calculated size. One clone, pPAP502, with the correct size was further analyzed and as expected, the *papG* gene was absent (cf. Table 3). Plasmid pPAP503 was constructed by ligating an *Eco*RI-*Hind*III fragment from pSKS106 carrying the *lac* promoter and the rightmost *Hind*III-*Bam*HI fragment of pDC5 to pBR322 digested with *Eco*RI and *Bam*HI. Plasmid pPAP504 was obtained by digesting pPAP503 with *Bgl*II and *Bam*HI, followed by religation at low DNA concentration. The plasmid pPAP507 was constructed by cloning the *Hind*III fragment of pDC5 carrying the genes equivalent to *papA*, *papH* and *papC* into the unique *Hind*III site of pPAP503 selecting for ampicillin resistance and screening for hemagglutination. This intermediate (pPAP506) was subsequently digested with *Bgl*II and *Bam*HI followed by religation giving pPAP507 in a manner analogous to the construction of pPAP504 from pPAP503.

Electron microscopy

Electron microscopy was performed using a JEOL 100B microscope with 100 mesh copper grids coated with thin films of 2% formvar. Bacteriz were resuspended in 10 mM Tris HCl (pH 7.5); 10 mM MgCl₂ and placed on the grid. The excess was immediately removed by aid of a filter paper. Grids were then washed with buffer and negatively stained for 5 seconds with 3.55% ammonium molybdate followed by washing with redistilled water.

RESULTS

Structural comparison of pPAP5 to pDC5 and pPIL10-35

- All three plasmids were shown to encode globoside-binding specificity (Table 2). The chromosomal inserts of the plasmids were mapped with several restriction endonucleases. To allow the detection of even small discrepancies in fragment size, the restriction enzyme digests of the different plasmids were analyzed in parallel slots by agarose gel electrophoresis. As shown in Fig. 1, the central *Sma*₁-*Kpn*₁ fragment is of the same size (4.6 kb) in all three plasmids. In pPAP5 this fragment codes for part of an additional gene as well as for the *papC* and *papD* genes. No differences were found in the physical map of this central fragment. Furthermore, a *Pst*_I fragment, approximately 370 bp in size and derived from the coding region of *papC* in pPAP5, hybridizes to a *Pst*_I fragment of equal size in pDC5 and pPIL110-35. Likewise, a 128 bp *Hpa*_I fragment from the N-terminal region of *papC* hybridizes to identically sized *Hpa*_I fragments from pDC5 and pPIL110-35. These observations show that the central region of the globoside-binding gene clusters, believed to encode export and assembly functions, is highly conserved.
- Plasmid pPIL110-35 carries a 5.7 kb DNA fragment that extends leftwards of the conserved *Sma*₁-*Kpn*₁ region. This region encompasses the structural gene for the F7₂ pilin, which holds a position equivalent to *papA*. The restriction site homology is not conserved in this region (Fig. 1). Also, a 221 nucleotide long probe from the central region of *papA* gave only a weak hybridization signal with pPIL110-35 even at low stringency, although the very 5' region of *papA* hybridized strongly under stringent conditions. This implies that the 5' end of the two pilin genes is highly conserved, whereas the central region appears to have diverged markedly.
- A DNA probe derived conventionally from the coding part of *papB* gave a strong hybridization signal with the 6.0 kb *Hind*_{III} fragment of pPIL110-35, suggesting that this gene is conserved and is present in equivalent positions in the two clones.

Three genes, *papE*, *papF* and *papG*, have been mapped to the *Sma*₃-*Bam*HI fragment of pPAP5. The restriction pattern of this fragment is less conserved in pDC5 and pPIL110-35 than is the central *Sma*₁-*Kpn*I fragment. The *Sma*₃-*Bgl*III fragment of pPAP5 carries *papE*, *papF* and the 5' half of *papG*. Using this fragment as a probe in Southern blotting experiments, signals of equal strength were detected in all three plasmids analyzed. The fragments that hybridize hold equivalent positions in the physical map of the three plasmids. On the other hand, a *Bgl*III-*Sma*₄ probe carrying the 3' half of *papG*, while giving a strong signal with pPAP5 DNA, did not hybridize to pDC5 or pPIL110-35 DNA even at low stringency. It should be noted that these two plasmids encode proteins that have a size similar to that of *papG* from this region. They also appear to have a similar restriction pattern, different from pPAP5, in the *papG* region. To more precisely define the borderline between homology and non-homology, a large number of M13 clones carrying defined regions of *papE*, *papF* and *papG* were used. Nick translated pDC5 and pPIL110-35 were used as probes. Positive hybridizations were detected with all M13 probes containing *papE* and *papF* DNA. None of the M13 clones carrying only *papG* DNA gave a positive signal. Thus, *papE* and *papF* are conserved, whereas there is a sharp decline in homology close to the end of *papF* and the start of *papG*.

Protein expression in minicells

Proteins expressed from pPAP5, pDC5 and pPIL110-35 were [³⁵S]-methionine labelled in *E. coli* minicells and the radiolabelled gene products were analyzed on 15% SDS-polyacrylamide gels. Proteins of similar molecular weight as *papB* and *papA* of pPAP5 were expressed from pPIL110-35, but not from pDC5. Both pDC5 and pPIL110-35 have been shown to express a protein, 71-75K (Clegg, S., and J.K. Pierce, "Organization of genes responsible for the production of mannose-resistant fimbriae of a uropathogenic *Escherichia coli* isolate", *Infect. Immun.* 42, 1983, pp. 900-906, and van Die, I. et al., "Molecular organisation of the genes involved in the production of F₇₂ fimbriae, causing mannose resistant haemagglutination, of a uropathogenic *Escherichia coli* 06:K2:H1:F7 strain", *Mol. Gen. Genet.* 194, 1984, pp.

528-533), mapping approximately at the same position as *papC* of pPAP5. The *papC* gene products of pDC5 and pPIL110-35 appeared as weakly expressed proteins with a slightly lower molecular weight than the PapC protein of pPAP5, whereas both pDC5 and pPIL110-35 expressed a protein with the same molecular weight as the PapD protein. For pPIL110-35 the gene encoding this protein has been mapped to the region corresponding to *papD* (van Die, I. et al., "Molecular organisation of the genes involved in the production of F₇₂ fimbriae, causing mannose resistant haemagglutination, of a uropathogenic *Escherichia coli* 06:K2:H1:F7 strain, *Mol. Gen. Genet.* 194, 1984, pp. 528-533). The PapE protein of pPAP5 has an apparent molecular weight of 16.5K. It was not possible to detect a protein of the same size in pDC5 and pPIL110-35, however, the slightly smaller protein expressed from both plasmids could be the *papE* gene product of these gene clusters. All three plasmids expressed a 15K protein which is known to be encoded by *papF* that is essential for globoside binding. The PapG protein of pPAP5 is a 35K polypeptide, and in both pDC5 and pPIL110-35 proteins with a slightly higher molecular weight were found. The *Bgl*II-*Bam*HI cutback derivative of pDC5, pPAP502, did not express the 36K polypeptide. This localizes the gene for this protein to the same region as *papG* in pPAP5.

A highly expressed 17K polypeptide from pDC5 and pPIL110-35 has been assigned to the distal *Sma*I-*Bam*HI fragment of these plasmids (Clegg, S., and J.K. Pierce, "Organization of genes responsible for the production of mannose-resistant fimbriae of a uropathogenic *Escherichia coli* isolate", *Infect. Immun.* 42, 1983, pp. 900-906, and van Die, I. et al., "Molecular organisation of the genes involved in the production of F₇₂ fimbriae, causing mannose resistant haemagglutination, of a uropathogenic *Escherichia coli* 06:K2:H1:F7 strain, *Mol. Gen. Genet.* 194, 1984, pp. 528-533). The pPAP5 constructs lack DNA equivalent to this region, consequently the 17K protein is not expressed from these plasmids or from pPAP502.

Complementation between the gene clusters on pPAP5 and pDC5

Since pDC5 contains DNA highly homologous to *papC*, *papD*, *papE* and *papF*, the question arose if pDC5 could be complemented by *papA* in pPAP5 to bring about the formation of a *papA* pilus. Consequently, pPAP43, which carries only the *papB* and *papA* genes and cannot surface localize the *papA* antigen, was constructed. Neither HB101 carrying this plasmid, nor the same strain with pDC5 was agglutinated by anti-pilus antiserum. When both these compatible plasmids were present in the same cell, however, the *papA* pilin was surface localized as demonstrated by antiserum agglutination. By electron microscopy it was confirmed that the *papA* pilin was assembled in the form of pili (data not shown). Neither pPAP43 nor pDC5 alone expressed surface localized pili when harbored in HB101.

To see if the adhesin function also could be complemented between the gene clusters, pPAP502 lacking the DNA from the *Bgl*II site to the *Bam*HI site at the rightmost end of pDC5 was constructed. Compared to pDC5, this derivative failed to express a 36K and a 17K polypeptide in minicells. It is assumed that, in agreement with mapping and hybridization data, the 36K protein corresponds to the 35K protein encoded by *papG* of the *pap* gene cluster. Plasmid pPAP502, in contrast to pDC5, did not mediate hemagglutination. Using pPAP16, a plasmid expressing *papE*, *papF* and *papG* in pPAP5, *in trans* it was possible to complement the deletion derivative pPAP502 to hemagglutination. Thus, also the adhesin function can be *trans*-complemented from one gene cluster to another, which is surprising, since the *papG* region is not well conserved between the clones. Plasmids pPAP18, pPAP17 and pPAP4 which are *papE1*, *papF1* and *papG1* mutants of pPAP16, (cf. General Materials and Methods above), respectively, failed to complement the deletion on pPAP502. Plasmid pPAP503, containing the *Hind*III-*Bam*HI fragment of pDC5 under *lac* promoter control also failed to hemagglutinate. However, pPAP503 could complement the defect in pPAP502 as shown by the positive hemagglutination reaction obtained with cells containing both these plasmids. As expected, a *Bgl*II-*Bam*HI deletion derivative of pPAP503 failed to accomplish this complementation (pPAP504 in Table 3). These plasmids were

used to complement mutations in the *pap* clone. It was shown that pPAP503 complemented all Tn5 insertion mutants in *papF* and *papG*, whereas the cutback derivative pPAP504 only complements those in *papF* (Table 3). The pDC5 derivative pPAP507 encoding the *papC*, *papD*, *papE* and *papF* gene equivalents complemented pSNO21 carrying a Tn5 mutation in the *papF* gene. These results show that proteins functionally similar to the *papF* and *papG* gene products are encoded by the corresponding regions on pDC5. From the experiments in the present Example, it may be concluded that the *papA* gene and to some extent the *papG* gene exhibit variability over the three *E. coli* strains, whereas the *papF* gene exhibits very little variability. It is not possible to decide whether *papG* or *papF* encodes for the specific binding protein.

TABLE 2

Characteristics of *E. coli* UTI strains and plasmid clones.
encoding their respective adhesin

5	Isolate	Serotype of isolate	Designation of plasmid clone	Serotype of cloned pilus antigen	Cloned specificity of binding
10	J96	O4:K6:H5	pPAP5	F."CI34.3"	Globoside
	IA2	O6:H-	pDC5	N.D.	Globoside
	AD110	O6:K2:H1	pPIL110-35	F7 ₂	Globoside

15 Globoside binding specificity was determined by positive slide hemagglutination (HA) of P₁-erythrocytes containing the globoside receptor and negative HA of p-erythrocytes which lack the globoside. Assay conditions were as described in General Materials and Methods above. N.D.: not determined.

TABLE 3

Surface expression of globoside-specific adhesin
by complementation between *pap* genes of pPAP5 and pDC5

5	Plasmid	-	pSNO21	pSNO42	pPAP502
	Mutation		<i>papF</i> ::Tn5-021	<i>papG</i> ::Tn5-042	Δ [<i>papG</i>]
	-	-	-	-	-
	pPAP16 wt	-	+	+	+
10	pPAP18 <i>papE1</i>	-	+	+	-
	pPAP17 <i>papF1</i>	-	-	+	-
	pPAP4 <i>papG1</i>	-	+	-	-
	pPAP503 Δ [<i>papB-D</i>]	-	+	+	+
	pPAP507 Δ [<i>papG</i>]	-	+	-	-
15	pPAP504 Δ [<i>papB-D</i>], Δ [<i>papG</i>]	-	+	-	-

Complementation of plasmid mutations harboured in HB101 was monitored by slide hemagglutination of P₁-erythrocytes as described in Materials and Methods and in General Materials and Methods above. The *papE1* and *papF1* mutations are non-polar mutations constructed by linker insertion mutagenesis (cf. General Materials and Methods above). The *papG1* mutation is a deletion of the *Sma*I₄-*Bam*HI fragment, thereby truncating the *papG* protein by ~1K, (cf. General Materials and Methods above). The Tn5 mutations *papF*::Tn5-021 and *papG*::Tn5-042 have been mapped to the *papF* and *papG* genes, respectively. Plasmids pPAP16, pPAP18, pPAP17 and pPAP4 are pPAP5 derivatives. Plasmids in the left column have a pBR322 (pMB1) replicon whereas plasmid in the top column have a pACYC184 (p15A) replicon. Genes within brackets, [], are pDC5 equivalents to the corresponding *pap* genes in pPAP5.

EXAMPLE 9

Hybridization of clinical isolates of *E. coli*

MATERIALS AND METHODS USED IN THIS EXAMPLE***Bacterial strains and plasmids***

- 5 The specimens consisted of 66 isolates of *E. coli*, collected from the urine of patients with significant bacteriuria ($>10^5$ bacteria/ml) and 96 fecal *E. coli* isolates obtained from healthy individuals. Plasmid pPAP5 carries a x kb large *EcoRI-BamHI* fragment from *E. coli* J96(0:4) that contains the entire *pap* gene cluster. The gene organisation is shown
- 10 in Fig. 2. Plasmid pDC5 codes for the globoside specific adhesin of the uropathogenic *E. coli* strain IA2(0:6). Recently it was shown that these two plasmids shown extensive homology over the major part of the *pap* gene cluster. However, DNA of pPAP5 derived from the *papG* gene did not hybridize to pDC5. DNA sequencing has confirmed
- 15 extensive differences between the *papG* genes in the two clones (Lund *et al.*, to be published).

Media and growth conditions

- The complete medium was Luria broth medium of Bertani supplemented with medium E and 0.2% glucose. The bacteria were grown at 37°C
- 20 with shaking. Luria broth agar plates without glucose were used for agglutination assay.

Receptor-binding assay

- For identification of digalactoside binding *E. coli*, bacterial cells grown for 22 hours on glucose-free Luria broth agar were resuspended
- 25 in a solution of latex beads coated with the digalactoside receptor. The cells were considered to express the adhesin if they agglutinated the beads within one minute.

Preparation of chromosomal DNA

Each bacterial isolate was grown in 100 ml LB-medium to 4×10^8 cells/ml. The bacteria were collected by centrifugation, suspended in 40 ml PBS (100 mM K-phosphate buffer, pH 7.2, 150 mM NaCl), recentrifugated and suspended in 5 ml PBS + 0.1 mg/ml proteinase K, 5 mM EDTA and 0.5% SDS (sodium dodecyl sulphate). The suspensions were incubated overnight at room temperature and finally extracted with phenol and precipitated with ethanol, repeated twice.

Preparation of ^{32}P -radiolabelled DNA fragments

- 10 Plasmid pPAP5 and pDC5 were digested with the appropriate restriction enzymes and DNA fragments were purified and ^{32}P -labelled by nicked translation.

Blotting and hybridization procedures

- 15 A dot-blot procedure was followed. 2 μg of chromosomal DNA was dissolved in 170 μl 0.1M Tris (pH 7.4). After the addition of 30 μl 2M NaOH and 100 μl 3M NaCl-0.3M sodium citrate, the mixture was incubated at 80°C for 20 minutes. The denatured DNA was chilled, neutralized with 40 μl 2M Tris (pH 7) and sucked through a 7 mm² area on a nitrocellulose filter, air dried and then baked in vacuo at 65°C for 20 12 hours. The filters were incubated for 2 hours in 10x Denhardt (Denhardt = 0.02% polyvinylpyrrolidone, 0.02% Ficoll, 0.02% BSA). They were once again incubated in a solution containing 4x SSC, 0.1% SDS, 2 mM EDTA, 10x Denhardt and 50 $\mu\text{g}/\text{ml}$ calf thymus DNA (heated for 3 minutes at 95°C) and incubated for one hour at 65°C. Finally 25 they were incubated with a radiolabelled probe in the same solution as described above for 16 hours in 60°C and then washed in 4x SSC 2x 5 minutes and 2x SSC 2x 20 minutes at 60°C and then air-dried. The filters were exposed to Dupont Cronex 4 X-ray film together with an intensifying screen at -70°C and then developed.

TABLE 4

Distribution of MR adhesins and hybridization
to *papE*, *papF* and *papG* DNA

5	Strain Nr.	ADHESINS					DNA hyb. probe		
		Human Pl	Swine p	Sheep	Cow	Galgal	Pap E,F	Pap G	Pap G
	1 Uri- nary tract isolates								
	J 96	+		+		+	+	+	+
	3163u 001	+	+			+	+		
	12007 002								
15	12014 003								
	12061 004	+		+		+	+		+
	12081 005			+		+	+		+
	12088 006								
20	12118 007								+
	12121 008								
	12144 009	+	+		+	+	+		+
	12154 010								
25	12159 011			+		+	+		+
	12257 012				+				
	12268 013				+	+	+		+
	12295 014	+	+		+				
	12297 015								
30	12335 016	+		+		+	+		+
	12340 017	+				+	+		+
	12382 018								
	12383 019	+		+	+	+	+		+
35	12389 020	+		+		+	+		+

Table 4 continued

	Strain Nr.	ADHESINS					DNA hyb. probe		
		Human Pl	Swine p	Sheep	Cow	Galgal	Pap E,F J96	Pap G	Pap G
5	1 Uri- nary tract isolates								
10	12390 021								
	12392 022								
	12409 023			+	+	+	+		+
	12418 024	+	+						
	12444 025								
15	12459 026								
	12483 027	+		+	+	+	+		+
	12496 028	+		+	+	+	+		+
	12497 029								
20	12501 030	+		+	+	+	+		+
	12516 031	+		+		+	+		+
	12564 032								
	12568 033								
25	12230 034	+		+		+	+		+
	12571 035				+	+	+		+
	12620 036	+		+		+	+		+
	12627 037								
30	12640 038								
	12654 039			+					
	12672 041								
	12708 042				+	+	+		+
	12724 043								
35	12725 044	+		+		+	+		+
	12722 045	+							

Table 4 continued

	Strain Nr.	ADHESINS					DNA hyb. probe		
		Human Pl	Swine p	Sheep	Cow	Galgal	Pap E,F J96	Pap G	Pap G
5	1 Uri- nary tract isolates								
10	12727 046	+		+		+	+		+
	12755 047								
	12756 048	+				+	+		+
	12767 049								
	12782 050	+				+	+		+
15	12908 051								
	12933 052								
	12970 053								
	13047 054	+				+	+		+
20	13058 055								+
	13060 056								+
	13122 057	+	+						+
	13131 058	+	+				+		+
25	13147 059								
	13176 060								
	13177 061								
	13236 062			+	+	+	+		
30	13341 063	+	+						+
	13347 064								
	13388 065								
	13389 066				+	+	+		+
35	13781 067								

Table 4 continued

		Strain Nr.	ADHESINS					DNA hyb. probe		
			Human PI	Swine p	Sheep	Cow	Galgai	Pap E,F J96	Pap G	Pap G pDC5
5		1 Fae- cal tract isolates								
10	2103	001F	+				+	+		+
	2104	002F								
	2109	003F								
	2110	004F								
	2111	005F	+	+			-	+		+
15	2112	006F								
	2113	007F								
	2124	008F								
	2130	009F								
	2133	010F			+		-			+
20	2134	011F								+
	2138	012F								
	2139	013F								
	2140	014F								
	2145	015F								+
25	2146	016F	+	+			-	+		
	2155	017F								
	2157	018F								
	2162	019F								+
	2171	020F								+
30	2172	021F								
	2173	022F	+				+	+		+
	2174	023F	+	+			-	+		+

Table 4 continued

		Strain Nr.	ADHESINS					DNA hyb. probe		
			Human	Swine	Sheep	Cow	Galgal	Pap E,F	Pap G	Pap G
5		1 Fae- cal tract isolates	PI	p					J96	pDC5
10	2177	024F								
	2179	025F								
15	2182	026F								
	2186	027F								
	2187	028F								
	2188	029F								
	2189	030F								
20	2190	031F								
	2191	032F								
	2195	033F								
	2196	034F								
	2197	035F								
25	2198	036F								
	2200	037F								
	2201	038F								
	2204	039F								
	2205	040F								
30	2212	041F								
	2213	042F								
	2214	043F								
	2216	044F								
35	2218	045F								

Table 4 continued

		Strain Nr.	ADHESINS					DNA hyb. probe		
			Human Pl	Swine p	Sheep	Cow	Galgal	Pap E,F J96pDC5	Pap G	Pap G
5		1 Fae- cal tract isolates								
10	2219	046F			-					+/-
	2224	047F								
	2225	048F	+	+	+		+	+		
	2226	049F								
	2227	050F								+/-
15	2229	051F								+/-
		052F								
		053F								
		054F								
20	2234	055F					+	+		+/-
		056F								
		057F								
25	2240	058F	+	+			+	+		+/-
		059F								
		060F								
30		061F								
		062F								
		063F								
		064F								
		065F								
35	2249	066F				+	-			
		067F								
		068F								

Table 4 continued

	Strain Nr.	ADHESINS					DNA hyb. probe		
		Human	Swine	Sheep	Cow	Galgal	Pap E,F	Pap G	Pap G
5	1 Faecal tract isolates	Pl	p					J96	pDC5
10	069F 070F								
15	071F 072F 073F 074F 075F								
20	2265 076F 077F 078F 079F 080F					-	+/-		
25	081F 082F 083F 084F 085F								
30	086F 087F 22286 088F 089F								+/-
35	090F								

Table 4 continued

	Strain Nr.	ADHESINS					DNA hyb. probe		
		Human	Swine	Sheep	Cow	Galgal	Pap E,F	Pap G	Pap G
5	1 Faecal tract isolates	PI	p					J96	pDC5
10	091F								
22290	092F		+	+		-	+		
	093F								
	094F								
	095F								
15	096F								

Hybridization hemagglutination results on E. coli isolates used in this study

		ISOLATES			
		Urine	Fecal		
5	P-spec MRHA	17	4		
	p-spec MRHA	7	3		
	Z-spec MRHA	10	3		
	Total MRHA	34	10		
	Non MRHA	32	86		
10		Urine strains (66 st)	Faecal strains (96 st)		
		Hybridization results			
		Pap E,F pPAP5	Pap G pDC5	Pap E,F pPAP5	Pap G pDC5
15		pos neg	pos neg	pos neg	pos
	neg				
	P-spec MRHA	16 1	16 1	4 0	3 1
	p-spec MRHA	3 4	4 3	3 0	2 1
20	Z-spec MRHA	8 2	7 3	1 2	1 2
	Total MRHA	27 7	27 7	8 2	6 4
	Non MRHA	0 32	3 29	2 84	9 77
	Total number of strains	27 39	30 36	10 86	15 81
	Latex beads positive	26 0	24 2	5	
25	Latex beads negative	1 39	6 34	5	
	Total number of strains	27 39	30 36	10	

P-spec MRHA: Including strains that also agglutinate animal erythrocytes.

30 p-spec MRHA: erythrocytes that agglutinate human p-blood.

Z-spec MRHA: no hemagglutination to human erythrocytes but to any of the following animal erythrocytes: Swine, sheep, cow.

The results obtained in this Example demonstrate that a large number of the clinical isolates of *E. coli* strains that bind to digalactoside have the E, F and G regions in their *pap* operons, and that strains that do not bind digalactoside do not have the E, F and G regions of the *pap* operon although they have the other regions in the operon.

CLAIMS

1. An antigen which, as its major immunizing component, comprises a determinant of an adhesin polypeptide or an immunogenically active subsequence thereof or a precursor therefor which is convertible to an immunologically active form, antibodies against which determinant
5 react with the adhesin polypeptide produced by pathogenic adhesin-forming bacteria which adhere to mammalian tissue.
2. An antigen according to claim 1 which comprises an amino acid sequence of at least 5 amino acids and up to the entire amino acid
10 sequence of the adhesin polypeptide.
3. An antigen according to claim 1 or 2 which binds to carbohydrate or protein receptors on mammalian tissue cells, or mammalian erythrocytes.
4. An antigen according to claim 3 which binds to a carbohydrate
15 receptor.
5. An antigen according to claim 4 which binds to a digalactoside-containing glycolipid or glycoprotein.
6. An antigen according to any of claims 1-5 which is derived from an adhesin-forming bacterium.
- 20 7. An antigen according to claim 6 in which the bacterium is a uropathogenic or enteropathogenic strain of *Escherichia coli* or other enteric bacteria or oral bacteria, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Neisseria catarrhalis*, *Yersinia spp.*, *Pseudomonas aeruginosa* or other *Pseudomonas spp.*, *Moraxella bovis* or other *Moraxella*
25 *spp.*, *Bacteroides nodosus*, *Staphylococcus spp.*, *Streptococcus spp.* or *Bordetella spp.* such as *Bordetella pertussis*.
8. An antigen according to any of claims 1-7 in which the adhesin polypeptide is a pilus adhesin polypeptide.

9. An antigen according to claim 8 in which the pilus adhesin polypeptide is a minor pilus component.

10. An antigen according to claim 9 which is derived from a pathogenic pilus-forming bacterium.

5 11. An antigen according to claim 10 in which the bacterium is a uropathogenic or enteropathogenic strain of *Escherichia coli*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Neisseria catarrhalis*, *Moraxella bovis* or other *Moraxella* spp., or *Bordetella pertussis*.

10 12. An antigen according to claim 11 in which the pathogenic strain of *E. coli* is a uropathogenic strain.

13. An antigen according to any of claims 1-12 which has the following amino acid sequence:

Met-Lys-Lys-Ile-Arg-Gly-Leu-Cys-Leu-Pro-Val-Met-Leu-Gly-Ala-Val-
 Leu-Met-Ser-Gln-His-Val-His-Ala-Val-Asp-Asn-Leu-Thr-Phe-Arg-Gly-
 15 Lys-Leu-Ile-Ile-Pro-Ala-Cys-Thr-Val-Ser-Asn-Thr-Thr-Val-Asp-Trp-
 Gln-Asp-Val-Glu-Ile-Gln-Thr-Leu-Ser-Gln-Asn-Gly-Asn-His-Glu-Lys-
 Glu-Phe-Thr-Val-Asn-Met-Arg-Cys-Pro-Tyr-Asn-Leu-Gly-Thr-Met-
 Lys-Val-Thr-Ile-Thr-Ala-Thr-Asn-Thr-Tyr-Asn-Asn-Ala-Ile-Leu-Val-
 Gln-Asn-Thr-Ser-Asn-Thr-Ser-Ser-Asp-Gly-Leu-Leu-Val-Tyr-Leu-
 20 Tyr-Asn-Ser-Asn-Ala-Gly-Asn-Ile-Gly-Thr-Ala-Ile-Thr-Leu-Gly-Thr-
 Pro-Phe-Thr-Pro-Gly-Lys-Ile-Thr-Gly-Asn-Asn-Ala-Asp-Lys-Thr-Ile-
 Ser-Leu-His-Ala-Lys-Leu-Gly-Tyr-Lys-Gly-Asn-Met-Gln-Asn-Leu-Ile-
 Ala-Gly-Pro-Phe-Ser-Ala-Thr-Ala-Thr-Leu-Val-Ala-Ser-Tyr-Ser

or any immunogenically active subsequence thereof.

25 14. An antigen according to any of claims 1-12 which has the following amino acid sequence:

Met-Ile-Arg-Leu-Ser-Leu-Phe-Ile-Ser-Leu-Leu-Leu-Thr-Ser-Val-Ala-
 Val-Leu-Ala-Asp-Val-Gln-Ile-Asn-Ile-Arg-Gly-Asn-Val-Tyr-Ile-Pro-
 Pro-Cys-Thr-Ile-Asn-Asn-Gly-Gln-Asn-Ile-Val-Val-Asp-Phe-Gly-Asn-
 30 Ile-Asn-Pro-Glu-His-Val-Asp-Asn-Ser-Arg-Gly-Glu-Val-Thr-Lys-Thr-

Ile-Ser-Ile-Ser-Cys-Pro-Tyr-Lys-Ser-Gly-Ser-Leu-Trp-Ile-Lys-Val-
 Thr-Gly-Asn-Thr-Met-Gly-Gly-Gly-Gln-Asn-Asn-Val-Leu-Ala-Thr-
 Asn-Ile-Thr-His-Phe-Gly-Ile-Ala-Leu-Tyr-Gln-Gly-Lys-Gly-Met-Ser-
 Thr-Pro-Leu-Ile-Leu-Gly-Asn-Gly-Ser-Gly-Asn-Gly-Tyr-Gly-Val-Thr-
 5 Ala-Gly-Leu-Asp-Thr-Ala-Arg-Ser-Thr-Phe-Thr-Phe-Thr-Ser-Val-
 Pro-Phe-Arg-Asn-Gly-Ser-Gly-Ile-Leu-Asn-Gly-Gly-Asp-Phe-Gln-
 Thr-Thr-Ala-Ser-Met-Ser-Met-Ile-Tyr-Asn

or any immunogenically active subsequence thereof.

15. An antigen according to any of claims 1-12 which has the following
 10 amino acid sequence:

Met-Lys-Lys-Trp-Phe-Pro-Ala-Phe-Leu-Phe-Leu-Ser-Leu-Ser-Gly-
 Gly-Asn-Asp-Ala-Leu-Ala-Gly-Trp-His-Asn-Val-Met-Phe-Tyr-Ala-
 Phe-Asn-Asp-Tyr-Leu-Thr-Thr-Asn-Ala-Gly-Asn-Val-Lys-Val-Ile-
 Asp-Gln-Pro-Gln-Leu-Tyr-Ile-Pro-Trp-Asn-Thr-Gly-Ser-Ala-Thr-Ala-
 15 Thr-Tyr-Tyr-Ser-Cys-Ser-Gly-Pro-Glu-Phe-Ala-Ser-Gly-Val-Tyr-
 Phe-Gln-Glu-Tyr-Leu-Ala-Trp-Met-Val-Val-Pro-Lys-His-Val-Tyr-Thr-
 Asn-Glu-Gly-Phe-Asn-Ile-Phe-Leu-Asp-Val-Gln-Ser-Lys-Tyr-Gly-
 Trp-Ser-Met-Glu-Asn-Glu-Asn-Asp-Lys-Asp-Phe-Tyr-Phe-Phe-Val-
 Asn-Gly-Tyr-Glu-Trp-Asp-Thr-Trp-Thr-Asn-Asn-Gly-Ala-Arg-Ile-
 20 Cys-Phe-Tyr-Pro-Gly-Asn-Met-Lys-Gln-Leu-Asn-Asn-Lys-Phe-Asn-
 Asp-Leu-Val-Phe-Arg-Val-Leu-Leu-Pro-Val-Asp-Leu-Pro-Lys-Gly-
 His-Tyr-Asn-Phe-Pro-Val-Arg-Tyr-Ile-Arg-Gly-Ile-Gln-His-His-Tyr-
 Tyr-Asp-Leu-Trp-Gln-Asp-His-Tyr-Lys-Met-Pro-Tyr-Asp-Gln-Ile-
 Lys-Gln-Leu-Pro-Ala-Thr-Asn-Thr-Leu-Met-Leu-Ser-Phe-Asp-Asn-
 25 Val-Gly-Gly-Cys-Gln-Pro-Ser-Thr-Gln-Val-Leu-Asn-Ile-Asp-His-Gly-
 Ser-Ile-Val-Ile-Asp-Arg-Ala-Asn-Gly-Asn-Ile-Ala-Ser-Gln-Thr-Leu-
 Ser-Ile-Tyr-Cys-Asp-Val-Pro-Val-Ser-Val-Lys-Ile-Ser-Leu-Leu-Arg-
 Asn-Thr-Pro-Pro-Ile-Tyr-Asn-Asn-Asn-Lys-Phe-Ser-Val-Gly-Leu-
 Gly-Asn-Gly-Trp-Asp-Ser-Ile-Ile-Ser-Leu-Asp-Gly-Val-Glu-Gln-Ser-
 30 Glu-Glu-Ile-Leu-Arg-Trp-Tyr-Thr-Ala-Gly-Ser-Lys-Thr-Val-Lys-Ile-
 Glu-Ser-Arg-Leu-Tyr-Gly-Glu-Glu-Gly-Lys-Arg-Lys-Pro-Gly-Glu-
 Leu-Ser-Gly-Ser-Met-Thr-Met-Val-Leu-Ser-Phe-Pro

or any immunogenically active subsequence thereof.

16. An antigen according to any of claims 8-15 which is substantially free from other components of the pilus.
17. An antigen according to any of claims 1-16 which is in substantially pure form.
- 5 18. An antibody raised against, or directed substantially only against, an antigen as defined in any of claims 1-17.
19. An antibody according to claim 18 which is obtained by immunizing an immunizable animal with an antigen as defined in any of claims 1-17.
- 10 20. An antibody according to claim 18 or 19 which is in substantially pure form.
21. A method of preparing an antibody according to claim 18 or 19 in which an immunizable animal is immunized with an antigen as defined in any of claims 1-17, and antiserum from the animal is obtained.
- 15 22. A method according to claim 21 in which the immunization is performed with a stabilized aqueous solution of an antigen as defined in any of claims 1-17.
23. A method according to claim 22 in which the stabilizing agent is a buffer or an adjuvant.
- 20 24. A method according to claim 23 in which the adjuvant is Freund's adjuvant or aluminium hydroxide.
- 25 25. A method of preparing an antibody according to claim 18 in which a hybridoma cell clone producing an antibody directed against an antigen as defined in any of claims 1-17 is grown in a suitable growth medium, and the antibodies formed are recovered from the culture.
26. A method according to claim 25 in which the gene or genes encoding the antibody are transferred from the hybridoma cell clone to

a suitable vector, the hybrid vector is transformed to a suitable bacterial host, the host is grown in an appropriate medium, and the antibody is recovered from the culture.

27. A method according to claim 26 in which the bacterial host is
5 *Escherichia coli* or *Bacillus subtilis*.

28. A vaccine for immunizing a mammalian subject against diseases caused by pathogenic bacteria which adhere to mammalian tissue, which contains an immunogenically effective amount of an antigen according to any of claims 1-17, optionally bound to a suitable carrier,
10 together with an immunologically acceptable vehicle.

29. A vaccine according to claim 28 in which the carrier is a physiologically acceptable polymer.

30. A method of preparing a vaccine according to claim 28 or 29 in which an immunogenically effective amount of an antigen as defined in any of claims 1-17, optionally bound to a suitable carrier, is combined
15 with an immunologically acceptable vehicle.

31. A method according to claim 30 in which the antigen comprises an amino acid sequence of at least 5 amino acids, and the carrier is a physiologically acceptable polymer to which the amino acid sequence
20 has been covalently bound.

32. A method according to claim 30 in which the nucleotide sequence encoding an antigen as defined in any of claims 1-17 is fused to the nucleotide sequence encoding a physiologically acceptable carrier polypeptide, the fused DNA sequence is inserted into a suitable vector, the hybrid vector is transformed to a suitable bacterial host, the
25 host is grown in an appropriate medium, and the fused polypeptide is recovered from the culture.

33. A DNA fragment which comprises at least the nucleotide sequence encoding an antigen as defined in claim 1, the DNA fragment preferably being one which encodes no other antigen.
30

34. A DNA fragment according to claim 33 which comprises the nucleotide sequence encoding the entire adhesin polypeptide.
35. A DNA fragment according to claim 33 which comprises the nucleotide sequence encoding a precursor of an adhesin polypeptide which is convertible to an immunogenically active form.
36. A DNA fragment according to claim 33 which comprises the nucleotide sequence encoding an immunogenically active subsequence of an adhesin polypeptide.
37. A DNA fragment according to any of claims 33-36 which has a length of at least 5 codons.
38. A DNA fragment according to any of claims 33-37 which is derived from an adhesin-forming bacterium.
39. A DNA fragment according to claim 38 which is derived from a uropathogenic or enteropathogenic strain of *Escherichia coli* or other enteric bacteria or oral bacteria, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Neisseria catarrhalis*, *Yersinia spp.*, *Pseudomonas aeruginosa* or other *Pseudomonas spp.*, *Moraxella bovis* or other *Moraxella spp.*, *Bacteroides nodosus*, *Staphylococcus spp.*, *Streptococcus spp.*, or *Bordetella spp.* such as *Bordetella pertussis*.
40. A DNA fragment according to any of claims 33-37 in which the adhesin polypeptide is a pilus adhesin polypeptide.
41. A DNA fragment according to claim 40 in which the pilus adhesin polypeptide is a minor pilus component.
42. A DNA fragment according to any of claim 33-41 which is derived from pathogenic pilus-forming bacteria.
43. A DNA fragment according to claim 42 in which the bacterium is a uropathogenic or enteropathogenic strain of *Escherichia coli*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Neisseria catarrhalis*, *Moraxella bovis* or other *Moraxella spp.*, or *Bordetella pertussis*.

44. A DNA fragment according to claim 43 in which the pathogenic strain of *E.coli* is a uropathogenic strain.

45. A DNA fragment according to claim 44 which has the following DNA sequence:

5 ATGAAAAAGATAAGAGGTTTGTGTCTTCCGGTAATGCTGGGGGCAGTGT-
TAATGTCTCAGCATGTACATGCAGTTGATAATCTGACCTTCAGAGGAAA-
ACTGATTATTCCTGCCTGTACTGTAAGCAACACAACACTGTTGACTGGCAG-
GATGTAGAGATTGAGACCTGAGTCAAAATGGAAATCACGAAAAAGAGT-
TTACTGTGAATATGCGGTGTCCCTATAATCTGGGAACAATGAAGGTTAC-
10 GATAACGGCAACAAACACTTATAACAATGCTATTTTAGTTCAGAATACA-
TCAAACACATCTTCTGATGGGTTACTCGTTTATCTTTATAACAGTAATG-
CAGGAAATATTGGGACTGCGATAACTTTAGGGACTCCATTTACGCCCCG-
AAAAATCACAGGTAATAATGCAGATAAACTATATCACTTCATGCCAAA-
CTTGATATAAAGGGAATATGCAGAATTTGATAGCCGGTCCTTTCTCT-
15 GCAACAGCAACGCTGGTTGCATCATATTCGTAA

or any subsequence thereof which, when expressed, constitutes an immunogenically active subsequence of the adhesin polypeptide encoded by the entire DNA sequence.

20 46. A DNA fragment according to claim 44 which has the following DNA sequence:

ATGATTCGTTTATCATTATTTATATCGTTGCTTCTGACATCGGTGCT-
GTACTGGCTGATGTGCAGATTAACATCAGGGGGAATGTTTATATCCCC-
CCATGCACCATTAATAACGGGCAGAATATTGTTGTTGATTTTGGGAAT-
ATTAATCCTGAGCACGTGGACAACCTCACGTGGTGAAGTCACAAAAACC-
25 ATAAGCATATCCTGTCCGTATAAGAGTGGCTCTCTCTGGATAAAAGTT-
ACGGGAAATACTATGGGAGGAGGTCAGAATAATGTACTGGCAACAAAT-
ATAACTCATTTTGGTATAGCGCTGTATCAGGGAAAAGGAATGTCAACAC-
CTCTTATATTAGGTAATGGTTCAGGAAATGGTTACGGAGTGACAGCAG-
GTCTGGACACAGCACGTTCAACGTTACCTTTACTTCAGTGCCCTTTC-
30 GTAATGGCAGCGGGATACTGAATGGCGGGGATTTCCAGACCACGGCCAG-
TATGAGCATGATTTATAACTGA

or any subsequence thereof which, when expressed, constitutes an immunogenically active subsequence of the adhesin polypeptide encoded by the entire DNA sequence.

47. A DNA fragment according to claim 44 which has the following
5 DNA sequence:

ATGAAAAAATGGTTCCTGCTTTTTTATTTTTATCCCTGTCAGGCGGT-
AATGATGCTTTAGCTGGATGGCACAATGTCATGTTTTATGCTTTTAAC-
GACTATTTAACTACAAATGCTGGTAATGTAAAGGTTATTGACCAACCT-
CAGCTATATATACCCTGGAATACAGGCTCTGCTACAGCAACTTATTAT-
10 TCGTGCTCAGGTCCGGAATTTGCGAGTGGAGTGTATTTTCAGGAGTAT-
CTGGCCTGGATGGTTGTTCCCTAACATGTCTATACTAATGAGGGGTTT-
AATATATTTCTTGATGTTTCAGAGCAAATATGGTTGGTCTATGGAGAAT-
GAAAATGACAAAGATTTTTACTTCTTTGTTAATGGTTATGAATGGGAT-
ACATGGACAAATAATGGTGCCCGTATATGTTTCTATCCTGGAAATATG-
15 AAGCAGTTGAACAATAAATTTAATGATTTAGTATTCAGGGTTCTTTTG-
CCAGTAGATCTCCCAAGGGACATTATAATTTTCCTGTGAGATATATA-
CGTGGAATACAGCACCATTACTATGATCTCTGGCAGGATCATTATAAA-
ATGCCTTACGATCAGATTAAGCAGCTACCTGCCACTAATACATTGATG-
TTATCATTCGATAATGTTGGGGGATGCCAGCCGTCAACACAAGTACTT-
20 AATATAGACCATGGGAGTATTGTGATTGATCGTGCTAACGGAAATATT-
AGCAAGTCAGACGCTTTCAATTTATTGCGATGTACCAGTTAGTGTAAG-
ATATCTCTGCTCAGAAATACACCACCAATATACAATAATAATAAATTT-
TCGGTTGGGTTAGGTAATGGCTGGGATTGCGATAATATCTCTTGATGGG-
GTTGAACAGAGTGAGGAAATATTACGCTGGTACACAGCCGGCTCAAAA-
25 ACAGTAAAGATTGAGAGCAGGTTGTATGGTGAAGAGGGAAAGAGAAAA-
CCCGGGGAGCTATCTGGTTCTATGACTATGGTTCTGAGTTTCCCCTGA

or any subsequence thereof which, when expressed, constitutes an immunogenically active subsequence of the adhesin polypeptide encoded by the entire DNA sequence.

- 30 48. A method of preparing an antigen comprising, as its major immunizing component, a determinant of an adhesin polypeptide, in which a bacterial host harbouring a hybrid vector containing an inserted DNA fragment which comprises at least the nucleotide sequence enco-

ding an antigen as defined in claim 1, the DNA fragment encoding substantially no other antigen, is cultivated, and the product expressed from the DNA fragment is recovered, optionally followed by purification.

- 5 49. A method according to claim 48 in which a DNA fragment encoding a first polypeptide comprising the adhesin polypeptide or an immunogenically active subsequence thereof or a precursor therefor which is convertible to an immunologically active form is fused to a DNA sequence encoding a second polypeptide, the fused DNA sequence is
10 inserted into a suitable bacterial host, the host is grown in an appropriate medium, the fused polypeptide is recovered from the culture and purified using an assay involving antibodies raised against the second polypeptide, and the second polypeptide is optionally cleaved off by means of a suitable protease followed by separation of the two
15 polypeptides.
50. A method according to claim 49 in which the DNA sequence encoding the second polypeptide is the *lacZ* gene encoding β -galactosidase.
51. A method according to any of claims 48-50 in which the DNA
20 fragment is the DNA fragment according to any of claims 33-47.
52. A method of preparing an antigen comprising, as its major immunizing component, a determinant of an adhesin polypeptide, in which the polypeptide or an immunogenically active subsequence thereof is prepared by peptide synthesis.
- 25 53. A method according to claim 52 in which the adhesin polypeptide is a pilus adhesin polypeptide.
54. A method according to claim 52 or 53 in which the polypeptide synthesized has a length of at least 5 amino acids.
55. A method according to any of claims 52-54 in which the polypeptide
30 tide is prepared by solid phase peptide synthesis.

56. A method according to claim 55 in which the carrier to which the initial amino acid is coupled during synthesis is a physiologically acceptable polymer useful as a carrier for the antigen in the vaccine according to claim 28 or 29.

5 57. A composition for the passive immunization of a mammalian subject against diseases caused by pathogenic bacteria which adhere to mammalian tissue, which comprises an immunologically effective amount of an antibody according to any of claims 18-20, optionally bound to a suitable carrier, together with an immunologically acceptable vehicle.

10 58. A composition according to claim 57 in which the carrier is a physiologically acceptable polymer.

59. A method of preparing a composition according to claim 57 or 58 in which an immunologically effective amount of an antibody according to any of claims 18-20, optionally bound to a suitable carrier, is
15 combined with an immunologically acceptable vehicle.

60. A diagnostic agent which comprises an antibody according to any of claims 18-20.

61. A diagnostic agent according to claim 60 in which the antibody is an antibody raised against an immunogenic determinant of a pilus
20 adhesin polypeptide.

62. A diagnostic agent which comprises an antibody raised against an immunological determinant other than the antigen defined in any of claims 1-17.

63. A diagnostic agent according to claim 62 which comprises an anti-
25 body raised against another polypeptide encoded by an adhesin gene cluster.

64. A diagnostic agent according to claim 63 in which the the antibody is an antibody raised against another pilus polypeptide.

65. A diagnostic agent which comprises a stable, labelled DNA sequence which is at least about 60% homologous with a DNA sequence in the bacterium to be detected.
- 5 66. A diagnostic agent according to claim 65 in which the DNA sequence has a length of at least 12 nucleotides.
67. A diagnostic agent according to claim 65 or 66 which is labelled with a radioactive labelling agent.
- 10 68. A diagnostic agent according to any of claims 65-67 in which the DNA sequence comprises a gene which is part of an adhesin gene cluster, but which does not encode the adhesin polypeptide itself, or a diagnostically effective subsequence thereof.
- 15 69. A diagnostic agent according to claim 68 in which the DNA sequence comprises a gene coding for a pilus polypeptide produced by a pathogenic pilus-forming bacterium which is not a pilus adhesin polypeptide, or a diagnostically effective subsequence thereof.
70. A diagnostic agent according to claim 69 in which the DNA sequence encoding the pilus polypeptide or a subsequence thereof is derived from a uropathogenic strain of *Escherichia coli*.
- 20 71. A diagnostic agent according to claim 70 in which the DNA sequence comprises the gene *papC* as defined in the specification or a diagnostically effective subsequence thereof.
72. A diagnostic agent according to claim 70 in which the DNA sequence comprises the gene *papD* as defined in the specification or a diagnostically effective subsequence thereof.
- 25 73. A diagnostic agent according to claim 70 in which the DNA sequence comprises the gene *papB* as defined in the specification or a diagnostically effective subsequence thereof.

74. A method of immunizing a mammal against diseases caused by pathogenic adhesin-forming bacteria which adhere to mammalian tissue, which comprises administering a vaccine containing an immunogenically effective amount of an antigen according to any of claims 1-17, optionally bound to a suitable carrier, or a composition for passive immunization containing an antibody according to any of claims 18-20, optionally bound to a suitable carrier, together with an immunologically acceptable vehicle.
75. A method according to claim 74 in which the bacteria are uropathogenic or enteropathogenic strains of *Escherichia coli* or other enteric bacteria or oral bacteria, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Neisseria catarrhalis*, *Yersinia* spp., *Pseudomonas aeruginosa* or other *Pseudomonas* spp., *Moraxella bovis* or other *Moraxella* spp., *Bacteroides nodosus*, *Staphylococcus* spp., *Streptococcus* spp., or *Bordetella* spp. such as *Bordetella pertussis*.
76. A method according to claim 75 in which the pathogenic bacteria are pilus-forming bacteria.
77. A method according to claim 76 in which the pathogenic bacteria are uropathogenic or enteropathogenic strains of *Escherichia coli*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Neisseria catarrhalis*, *Moraxella bovis* or other *Moraxella* spp., or *Bordetella pertussis*.
78. A method of determining receptor density or distribution in a host mammal such as a human, comprising treating a tissue sample from the host with a receptor-specific polypeptide, removing unbound receptor-specific polypeptide and determining the amount of receptor-specific polypeptide bound.
79. A method according to claim 78 wherein the receptor-specific polypeptide is an adhesin polypeptide.
80. A method according to claim 79 wherein the adhesin polypeptide is an adhesin polypeptide of a uropathogenic strain of *E. coli*.

81. A method for preventing or reducing the possibility of infection of a human being or other mammal with a pathogenic adhesin-binding microorganism, comprising treating the human being or other mammal with one or more adhesin polypeptides so as to distribute the polypeptides over the cell surfaces for which infection with a specific pathogenic bacteria is to be prevented, the adhesin polypeptide used being an adhesin polypeptide that will bind with the receptors with which the adhesin generated by the pathogenic bacteria will bind.

Fig. 1






Fig. 2



2/3

Fig. 3



INTERNATIONAL SEARCH REPORT

International Application No PCT/DK85/00045

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC ⁴		
A 61 K 39/00, 108, C 07 K 13/00, 15/04, C 12 N 15/00		
II. FIELDS SEARCHED		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
IPC	A 61 K 39/00, 02, 08; C 07 G 7/00; C 12 N 15/00;	
	C 07 K 13/00, 15/00, 04	
US CI	424:88, 92; 435:172	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
SE, NO, DK, FI classes as above		
III. DOCUMENTS CONSIDERED TO BE RELEVANT *		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
X	EP, A1, 102 831 (UNILEVER MV) 14 March 1984 & GB, 2126236 AU, 18538/83 JP, 59073528	1-8, 17-24, 28-31, 57-62, 74-77
X	EP, A1, 89 940 (SVENSKA SOCKERFABRIKS AB) 28 September 1983, see in particular example 9, 5 and 6.	1-8
Y	EP, A2, 84 522 (SANDOZ-PATENT GMBH) 27 July 1983, p 28-31, 34-36, 41-42, 57-58 and 77-80 & WO, 83/02456	32-56
X	EP, A2, 77 734 (MOLECULAR GENETICS INC) 27 April 1983 & AU, 89454/82 JP, 58099423 US, 4443549 CA, 1187822	18-25, 60-62
.../...		
<p>* Special categories of cited documents: **</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
1985-07-11	1985-07-23	
International Searching Authority	Signature of Authorized Official	
Swedish Patent Office	Carl-Olof Gustafsson	

L.E.

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 81, because they relate to subject matter not required to be searched by this Authority, namely:

Method for treatment of the human or animal body
by therapy (Rule 39)

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers _____, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 8.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This international Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category*	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X,Y	GB, A, 2 094 314 (THE WELLCOME FOUNDATION LIM) 15 September 1982	1-8, 28-40, 42, 43, 48- 51, 74-77/ 9-17, 44-47, 65-73
E	US, A, 4 461 838 (BRINTON C.C., MC MICHAEL J.C.) 24 July 1984	
E	US, A, 4 454 116 (BRINTON C.C.) 12 June 1984	
E	US, A, 4 454 117 (BRINTON C.C.) 12 June 1984	
X	US, A, 4 237 115 (BRINTON C.C.) 2 December 1980 & US, 4454116	1-8
X	US, A, 4 311 797 (KHACHATOURIANS G.G.) 19 January 1982 & CA, 1146882	1-8
X	US, A, 4 443 431 (BUCHANAN T.M. et al) 17 April 1984	1-11
X	US, A, 4 136 167 (PARY S.H. PORTER P.) 23 January 1979 & US, 4157390 NL, 7606379 FR, 2313942 BE, 842814 DE, 2626350 AU, 14705/76 GB, 1553664 JP, 51151322 CA, 1061252 AU, 513801	1-8
X	US, A, 4 157 390 (PARY S.H. PORTER P.) 5 June 1979 & US, 4136167 NL, 7606379 FR, 2313942 BE, 842814 DE, 2626350 AU, 14705/76 GB, 1553664 JP, 51151322 CA, 1061252 AU, 513801	1-8
	.../...	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	US, A, 4 343 792 (GOUET P. et al) 10 August 1982 & EP, 0028172 FR, 2466251 US, 4443547	1-8
X	EP, A2, 60 129 (CETUS CORP.) 15 September 1982 & WO, 82/03088 JP, 57171926	1-8, 28-40, 48-51, 74-77
X	EP, A1, 80 412 (INSTITUT MERIEUX) 1 June 1983 & FR, 2516385	1-8
X	GB, A, 1 472 624 (CANADIAN PATENTS AND DEVELOPMENT LIM) 4 May 1977 & BE, 832967 NL, 7510120 FR, 2282908 BE, 2538994 AU, 84409/75 JP, 51051514	1-8
X	GB, A, 1 549 345 (BACTEX INC) 1 August 1979 & NL, 7604311 BE, 841068 FR, 2308377 DE, 2617870 AU, 13321/76 CA, 1050423 JP, 51130525 AU, 509621 CH, 634923 US, 4461838	1-8
Y	Progr. Allergy Vol 33, p 80-105 published 1983 (Ørskov I, Ørskov F) "Serology of Esch- erichia coli Fimbriae".	1-77
Y	Progr. Allergy Vol 33, p 189-202 published 1983 (Svanborg Edén C. et al) "Aspects on Structure and Function of Pili on Uropatho- genic Escherichia coli".	1-77
 / ...	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	Microbiological Reviews Vol 46, p 129-61 published 1982 (Gaastra W. de Graaf F.K.) "Host-Specific Fimbrial Adhesins of Noninvasive Enterotoxigenic Escherichia coli Strains".	1-77
Y	J. Bacteriology Vol 157, p 330-33 published January 1984 (Båga M et al) "Nucleotide Sequence of the papA Gene Encoding the Pap Pilus Subunit of Human Uropathogenic Escherichia coli".	1-77
Y	J. Bacteriology Vol 153, p 955-61 published 1983 (Worobec E.A. et al) "Localization of the Major Antigenic Determinant of EDP208 Pili at the N-Terminus of the Pilus Protein".	1-77
X	Infection Vol 11, p 6-12, published January-February 1983 (Svenson S.B. Källénus G.) "Density and localization of P-fimbriae-specific receptors on mammalian cells: Fluorescens - activated cell analysis.	78-80
T	J. Bacteriology Vol 159, p 482-87 published August 1984 (MOOI F.R et al) "K88ae Gene of Escherichia coli Encodes a Fimbria-Like Protein Distinct from the K88ab Fimbrial Adhesin".	
T	EMBO J. Vol 3, p 1159-65 published May 1984 (Norgren M et al) "Mutations in E coli cistrons affecting adhesion to human cells do not abolish Pap pili fiber formation".	
T	Eur. J. Biochem Vol. 143, s. 395-99 published september 1984 (Klemm P.) "The fim A gene encoding the type-1 fimbrial subunit of Escherichia coli".	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)